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The aim of this thesis was to investigate the effect of various parameters in patients
with chronic liver disease before liver transplantation and their influence on the
occurrence of acute rejection following transplant. This may be useful in tailoring
immunosuppression to avoid adverse effects in patients less likely to develop acute
rejection.
Firstly a retrospective analysis of patients transplanted between 1992 and 1997 was
undertaken. This showed that patients who were younger and had less severe liver
disease were more likely to suffer acute rejection. It also showed that acute rejection
was less likely to occur in patients with depleted protein stores as measured by mid-
arm muscle circumference and those with alcoholic liver disease. Multivariate
analysis found that a depleted mid-arm muscle circumference was independently
associated with a reduced incidence of acute rejection.
A lymphocytotoxic cross-match between the patients serum and the donor T
lymphocytes was also studied. This did not show any influence on a single episode of
acute rejection but a postitive test was found in significantly more patients with
recurrent acute rejection and in those with early graft failure.
The role of cytokines in acute rejection is not clear but animal and human studies had
suggested that tumour necrosis factor alpha (TNF-a) played some role.
Polymorphisms in the genes encoding TNFa, interleukin 10 and transforming growth
factor betal (TGF(31) which influence in vitro production of cytokines were examined
in transplant patients. This showed an increase in the TNFa 2 polymorphism at
position -308 in patients with acute rejection but no association with IL-10 or TGFpi
polymorphisms.
Pre-transplant levels of TNFa and IL-10 were measured following stimulation of
peripheral blood mononuclear cells with lipopolysaccharide from patients with
chronic liver disease. PBMC were preincubated with different immunosupressants.
There was increased production of stimulated TNFa pretransplant in patients who
went on to develop acute rejection. No relationship was found between IL-10
production and acute rejection.There were differences in the effects of tacrolimus,
cyclosporin and dexamethasone on the production of both cytokines.
The pre-transplant immune status of patients was assessed by contact sensitisation to
diphenylcyclopropenone (DPC). This demonstrated that patients unable to mount an
immune response to DPC did not require treatment for acute rejection following liver
transplantation. It also demonstrated a correlation between the strength of reaction to
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7. CONCLUSIONS AND AIMS
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1. HISTORY
The first orthotopic liver transplant in humans was carried out by Starzl in 1963
followed by the first reports of extended survival in 1967 (Starzl, 1968) with the
emergence of immunosuppression with antilymphocyte globulin, azathioprine and
corticosteroids. The improvement in liver preservation and the introduction of
cyclosporin inl979 (Calne et al.,1979) led to significant improvement in survival. The
realization that the procedure was surgically feasible with adequate survival led to
acceptance by the National Institute of Health in 1983 that orthotopic liver
transplantation was no longer experimental. At present around 4000 transplants are
performed each year in the United States (UNOS data source) and around 3500 in
Europe (European Liver Transplant Registry).
The first series from the United Kingdom was reported in 1973 from the Kings-
Cambridge group (Williams et al., 1973). There are now seven centres within the U.K.
which perform orthotopic liver transplantation, and in total they perform around 500
transplants per year (United Kingdom Transplant Support Services Authority).
The majority of orthotopic liver transplants are performed in patients with end-stage
chronic liver disease, acute liver failure when the native liver is unlikely to recover
spontaneously, and intra-hepatic malignancies. The proportion of patients transplanted
for each indication reflects the geographical variation in the causes of acute and
chronic liver disease with chronic hepatitis C related cirrhosis now being the
commonest indication worldwide (Terrault, 2000).
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2. REJECTION
The initial experiments in liver transplantation were carried out in dogs, and it became
clear that rejection of the transplanted liver was a major problem (Moore, 1960). The
use of immunosuppressive therapy in the form of anti-lymphocyte serum and
azathioprine and the finding of less severe rejection in pigs did however provide some
hope that long-term survival may be possible in humans.
Rejection occurs as a result of genetic disparity between the donor and recipient. In
syngeneic animals there is no rejection of organ transplants. Rejection in liver
transplantation can be hyperacute, acute or chronic (Adams and Neuberger, 1990).
2.1 INCIDENCE OF REJECTION
Hyperacute rejection in liver tranplantation is rare and results in early graft loss. It is
thought to be caused by preformed antibodies resulting in activation of complement
and graft destruction.
Acute cellular rejection occurs in between 24-80% of liver transplants (Fisher et al,
1995). The incidence varies depending on the initial immunosuppression regimens.
There is no evidence to suggest that acute cellular rejection increases mortality. There
are reports suggesting that morbidity is increased in patients who suffer from acute
cellular rejection (Fisher et al., 1995) although this is not every centre's experience
(Neuberger, 1995). A recent report from the U.S. suggests that there is a significant
7
cost associated with the treatment of an episode of acute cellular rejection (Martin et
al., 1997).
Recent reports of graft outcome following acute rejection suggest that graft outcome
following a single episode of rejection is not detrimental (Dousset et al., 1998;
Wiesner et al., 1998; Avollo et al., 1998; Neuberger and Adams, 1998). The studies
by Avollo and Wiesner suggest in fact that graft outcome may in fact be improved
following a single episode of acute rejection. Severe acute rejection does however
seem to adversely affect graft outcome, as does acute rejection in patients transplanted
for hepatitis C related liver disease (Wiesner et al., 1998).
The incidence of chronic rejection is diminishing and the number of grafts lost now is
around 5% (Wiesner et al., 1999). The improvement in immunosuppression is likely
to be the principal reason for this.
2.2 HISTOPATHOLOGY
The histological changes of acute cellular rejection typically present as a triad which
was first observed by Snover et al. in 1984. The triad consists of portal inflammation,
bile duct damage and venous endothelialitis.
(A) Portal inflammation consists of a mixed infiltrate containing lymphocytes,
neutrophils, eosinophils and often blast like cells. The inflammatory infiltrate can spill
over into the periportal parenchyma.
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(B) Bile duct inflammation and damage varies from a minority of ducts being
infiltrated by inflammatory cells to most or all ducts showing degenerative changes ,
such as nuclear pleomorphism or cytoplasmic vacuolisation of the epithelium. Focal
luminal disruption and duct loss can also occur.
(C) Venous endothelialitis involving the portal and or hepatic venules ranges from
lymphoid attachment to the luminal surface of the endothelium, to subendothelial
lymphocytic infiltration affecting most venules with extension into the perivenular
parenchyma.
Figure 1 shows allograft biopsies showing no acute rejection and the typical features
of acute cellular rejection.
The occurrence of other histological findings such as arteritis and perivenular
necrosis without inflammation, hepatocyte ballooning and interstitial haemorrhage do
occur in acute rejection but are poorly reproducible.
2.3 GRADING SYSTEMS
At least two of the above triad are required for a histopathological diagnosis of acute
rejection. The need for a simple, reproducible and clinically relevant grading system
has been acknowledged and an international consensus document was published in
1997 (Demetris et al., 1997). The development of grading systems by individual
centres eg. Pittsburgh and Birmingham, made it difficult for comparisons to be made
between centres in considering the requirement for additional therapy. The first
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attempt at making a grading system using multiple pathologists and patients from
more than one centre came from the National Institute of Diabetes and Digestive and
Kidney Diseases Liver Transplantation database in 1995 (Demetris et al., 1995), but it
was felt to be too difficult to follow. The consensus document in 1997 proposed a
system incorporating an overall grade i.e. indeterminate (portal infiltrate fails to meet
criteria for acute rejection), mild - affecting only a minority of portal triads and
confined to the triad, moderate- infiltrate expanding most or all triads and severe- as
moderate with periportal spillover and moderate to severe perivenular inflammation
that extends into the hepatic parenchyma and is associated with perivenular
hepatocyte necrosis. In addition to this global assessment the authors proposed a
rejection activity index (RAI) which was a semiquantitive score equal to the sum of
the severity (0-3) of inflammation/damage occurring within the portal triad, bile duct
and venous endothelium. Therefore a RAI of 0 indicated no acute rejection whereas
an RAI of 6 indicated moderate rejection. It was felt that the RAI would be most
useful in academic centres when it could be used in evaluating new treatment
schedules etc.
3. DEFINITION AND CLINICAL FEATURES
3.1 Acute rejection
Acute cellular rejection has been defined by an International Working Party (1995) as
inflammation of the allograft elicited by a genetic disparity between the donor and
recipient, primarily affecting interlobular bile ducts and vascular endothelia including
portal and hepatic veins and occasionally the hepatic artery and its branches.
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Acute rejection usually occurs within the first 30 days following transplantation. In
mild acute rejection there are often no clinical findings. However in severe acute
rejection the patient may complain ofmalaise and be pyrexial with swelling and
tenderness of the graft. Occasionally, ascites develops due to the increase in
intrahepatic pressure secondary to liver swelling.
Acute rejection is difficult to diagnose without histology. Liver enzymes are often
increased and a rise or cessation in the fall of bilirubin is seen, but these are neither
sensitive nor specific. No correlation has been found between liver tests and the
histologic severity of acute rejection (Adams and Neuberger, 1998). The eosinophil
count may be raised during acute cellular rejection (Dollinger et al., 1996) and various
serum markers of immune activation and adhesion molecules have shown associations
with rejection but with poor sensitivity and specificity (Adams et al., 1989;Lalli et al.,
1992; Fabrega et al., 2000). The diagnosis of rejection therefore usually requires
histology. Most centres obtain percutaneous core needle biopsies although some
centres use a fine-needle aspiration technique.
3.2 Chronic rejection
Chronic rejection is defined by two main histopathologic features -loss of bile ducts
and obliterative vasculopathy. These components usually co-exist but may occur
independently. The diagnosis is difficult to make on a single biopsy as the foam cell
arteriopathy usually involves larger vessels. The loss of small bile ducts in more than
50% of portal triads is indicative of chronic rejection although it can be seen in other
complications e.g. bile duct strictures and cytomegalovirus infection. A recent
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consensus document has been published proposing a standardised definition
(International panel, 2000).
Chronic rejection usually does not occur before 60 days following transplantation and
may develop after an unresolved episode of acute rejection or following multiple
episodes of acute rejection. In some cases it may occur indolently over a period of
months to years with no clinically apparent acute rejection episodes. In addition to the
genetic disparity between the donor and recipient there have been reports of other risk
factors such as recipient age, CMV infection (Evans et ah, 2000) and low cyclosporin
levels in the early postoperative days (Wiesner et al., 1999).
4.1 TREATMENT OF ACUTE REJECTION
The treatment of established acute rejection is with high dose corticosteroids. The
threshold for treatment varies between centres and individuals. The regimes used vary
and include oral prednisolone (100-200mg/day for 3 days), intravenous
hydrocortisone (up to lg/day for 3 days) or methylprednisolone (500-1 OOOmg/day for
3 days). There is little evidence to support any particular regimen. The use of
monoclonal antibodies directed against T lymphocytes e.g. OKT3 have not proved to
be of benefit in the initial therapy of acute rejection but may be of benefit in the
treatment of steroid-resistant rejection. Recent evidence has suggested that an increase
in the dose of tacrolimus alone may be sufficient for the treatment of acute rejection
(Boillot, 1998).
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The vast majority of episodes of acute rejection respond to corticosteroids. In some
cases however there is no improvement in liver function tests, and repeat biopsy
reveals ongoing rejection. The rate of steroid resistant rejection varies from 7-18%
and can depend on the immunosuppressive agents used. The treatment of steroid
resistant rejection is with a switch from cyclosporin to tacrolimus (Klintmalm et al,
1993 ) or in some cases with OKT3 monoclonal antibody. There is some evidence to
suggest that late acute rejection occurring after 30 days may be less steroid responsive
with the identified risk factors being concomitant viral infection and low
immunosuppressant levels (Cakaloglu et al., 1995; Mor et al., 1992). There is an
increased incidence of chronic rejection in patients who suffer late acute rejection
(Neuberger and Adams, 1998) or steroid-resistant rejection (Wiesner et al, 1999). The
reason for the different outcomes of early and late acute rejection is not clear. It may
be that late rejection represents a more aggressive form of rejection reflecting T cell
escape from immunosuppression. Alternatively it may be that the more severe
episodes of acute rejection are clinically apparent after the initial post-operative
period when acute rejection is actively sought (Neuberger and Adams, 1998).
4.2 TREATMENT OF CHRONIC REJECTION
There is no therapy for advanced chronic rejection except re-transplantation. Studies
have shown that a switch to tacrolimus from cyclosporin early in the process before
the bilirubin is above 170 pmol/1 may improve graft function and lead to a reduction
in bilirubin (Sher et al., 1997) although no controlled study has been done.
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5. MECHANISM OF ACUTE REJECTION
5.1 MAJOR HISTOCOMPATIBILITY COMPLEX
The polymorphic membrane-bound glycoproteins termed the Major
Histocompatability Complex (MHC) are involved both in the recognition of self and
in the activation of the immune system. MHC class I molecules are found on almost
all nucleated cells whereas MHC class II molecules are largely limited to cells of the
immune system. The antigen presenting cells (APC) express MHC class II molecules
on their surface with antigenic polypeptides which can be recognised by T
lymphocytes. Some of the terms used in transplantation immunology are outlined
below.
Term Definition
Syngeneic Genetically identical, e.g. monozygotic
twins, mice of same strain
Allogeneic Genetically non-identical but of the same
species, e.g. cadaveric liver transplant
Alloresponse Immune response to the antigens present in
an allogeneic graft
Alloantigen Target antigens in an allogeneic graft
In transplantation of solid organs, genetic disparity exists between donor and
recipient. The allogeneic MHC molecules are recognised as foreign by host T
lymphocytes (Lechler, 1990) and in the case of liver transplantation it is thought that
donor APC such as dendritic cells migrate from the liver and encounter host T-
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lymphocytes in host lymph nodes. This is the called the direct recognition pathway.
The evidence for the involvement of this pathway in acute rejection comes from
various approaches. There is an increase in the precursor frequency of T cells
recognizing an allogeneic MHC molecule directly some 100 times that of T cells
responding to the same MHC indirectly (Liu et al., 1993). Secondly, the reduction of
donor APC within grafts leads to a marked reduction in acute rejection (Lechler et al.,
1982). In addition pretreatment of donor grafts to increase the number of dendritic
cells leads to rejection of grafts which are normally accepted indefinitely (Steptoe et
al, 1998). Finally, adoptive transfer of T cell lines specific for direct recognition of rat
allogeneic MHC lead to acute rejection in immunocompromised recipients (Braun et
al., 1993). A schematic representation of the direct recognition pathway is shown in
figure 1.2.
The indirect pathway involves the processing of donor derived MHC-molecules by
host APC which then present this peptide in the context of selfMHC to host T
lymphocytes. The indirect pathway is thought to play less of a role in allorecogniton
and rejection although there is evidence to support it in liver transplantation (Molajoni
et al., 1997) and it may have a role in chronic rejection (Shirwan, 1999). A schematic
representation of the process of indirect recognition is shown in figure 1.3.
The expression of MHC class I molecules in normal liver is only weak or negative on
hepatocytes (Fleming, 1981;Steinhoff, 1988), whereas biliary epithelium and vascular
endothelium express these molecules strongly (Daar, 1984). MHC class II molecules
are largely on the Kupffer cells in normal liver with both hepatocytes and biliary
epithelium having no expression (Steinhoff, 1988;Daar, 1984). During acute allograft
16
Activated cytotoxic T cell
Fig 1.2. Proposed mechanism of direct recognition pathway. (APC = antigen
presenting cell, MHC =major histocompatibility complex,CD = cluster of
differentiation, Tc = cytotoxic T cell, Th = helper T cell)
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SELF APC
Figure 1.3. Indirect pathway of recognition of alloantigen by self antigen presenting cell
(APC) resulting in activation and proliferation of cytotoxic T cells, B cells and macrophages.
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rejection there is altered expression ofMHC molecules with an induction ofMHC
class I on hepatocytes and MHC class II on biliary epithelium and vascular
endothelium (Steinhoff, 1988;So, 1987). The induction ofMHC molecules leads to
different liver components becoming targets for the immune response in graft
rejection. There is evidence to suggest that MHC expression correlates with rejection
(So, 1987) although this was not substantiated by Rouger et al. in 1990.
5.2 INFILTRATING CELLS
The inflammatory infiltrate in acute cellular rejection is composed principally of
activated T cells, B cells, activated lympoblastoid cells. Studies investigating the
phenotype of the T cells have been conflicting. Ibrahim et al.(l 993) found the portal
infiltrate to be composed principally of CD8+ T cells whereas Wong et al.(l998)
found little difference between the number of CD4+ and CD8+ T cells. A study by
Dollinger et al.(l 998) however, found an increase in CD4+ T cells in rejecting liver
tissue. This study also showed these cells to express markers of proliferation. These
CD4+ cells are thought to be the principal source of cytokines which are responsible
for the further activation and expansion of the immune response. The cytotoxic T cells
(CTL) are thought to be the principal source of damage to the graft. There is evidence
that the mechanism of cell death is by apoptosis rather than necrosis. The two major
pathways utilised by the CTL are the Fas/Fas ligand pathway and the perforin-
dependent granule-exocytosis pathway by the release of granzyme B. Studies
involving tissue from liver, heart and kidney allografts have shown an increase in
granzyme B during or preceding acute rejection rejection (Krams et al., 1995;Hayashi
et al., 1995;Legros-Maida et al., 1994;Lipman et al., 1994). It is likely that the
19
Fas/FasL pathway is also used as a pathway of allograft damage (Krams and
Martinez, 1998).
5.3 CO-STIMULATION
In addition to the antigen specific recognition reaction involving MHC and T cell
receptors there is an additional, non antigen-specific, co-stimulation signal which is
required for an effective immune response. The best characterized receptor on T cells
is the CD28 molecule although there are other molecules on T cells which can serve
as co-stimulatory receptors. The ligands for CD28 are B7-1 (CD80) and B7-2 (CD86)
which are present on activated antigen presenting cells. CTLA4 is also expressed on T
cells and binds B7-1 and B7-2 with an inhibitory signal.
In the absence of co-stimulatory signals, the T cell which encounters antigen does not
divide and does not produce appreciable levels of cytokine. The outcome for the T
cell which does not receive a co-stimulatory signal is either anergy (Gimmi, 1993) or
apoptosis (Noel, 1996).
Another pathway recently characterised and thought to play a role in T cell
stimulation is the CD40:CD40 ligand pathway. CD 40 is expressed on Bcells,
dendritic cells and macrophages. The CD40 ligand (CD154) is expressed on activated
CD4 T cells. Stimulation of the CD40 molecule on B cells results in signals for
antibody production and B7 expression (Hancock et al, 1996;Ranheim et ah, 1993).
CD 40 stimulation on APC leads to the production of cytokines and adhesion
molecules involved in T cell activation (Guo et ah, 1996).
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The role of these molecules for potential targets for therapy in transplantation is
significant. The delivery ofCTLA4-Ig to the donor liver prior to transplantation
prevented rejection in a rat model (Olthoff et al., 1997). The blockade of both co-
stimulatory pathways has also led to prolonged rejection-free survival of renal
transplants in primates (Kirk et al., 1999).
5.4 TOLERANCE
The definition of tolerance is not straightforward. The initial use of the term by Starzl
implied a reduced amount of immunosuppression to maintain graft function. Others
have used the term clinical tolerance when immunosuppression has been withdrawn
with no apparent rejection of the allograft. The finding that donor cells were found in
distant host lymphoid sites led to the hypothesis that microchaemerism may lead to
tolerance. However a study of immunosuppression withdrawal did not find any
difference in rejection rates between recipients with microchaemerism and those
without (Devlin et al., 1998).
Immunological tolerance however is defined as an unresponsiveness to donor
antigens. The mechanism of tolerance in animal models where no immunosuppression
is required is not clearly understood, but T cell anergy has been proposed as a
possibility. This has been proposed to occur by a mechanism whereby T cell receptors
encounter donor antigen but do not receive a co-stimulatory signal and therefore do
not elicit an immune response when this antigen is encountered again. There are
studies which support this theory (Turka et al., 1992; Pearson et al., 1994) although this
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is unlikely to be the sole mechanism. Studies investigating the systemic hypo-
responsiveness to donor antigen induced by liver transplantation have found that cells
are in fact still responsive in vitro leading to the term split tolerance (Dahmen et al,
1994). This suggests that there is in fact an active regulation or suppression of these
donor reactive cells in vivo.
5.5 CYTOKINES
As indicated previously the augmentation of the immune response following
allorecognition involves the release and action of the soluble mediators termed
cytokines. Cytokines such as tumour necrosis factor alpha (TNF-a) can induce
damage via cell receptor pathways. The principal source of TNF-a is thought to be
infiltrating monocytes from the recipient (Teramoto et al., 1998). The other principal
cytokines are produced by CD4+ T cells. These cytokines are responsible for the
upregulation ofMHC expression, T cell proliferation, cytotoxic T cell differentiation
and alloantibody production. There are thought to be distinct subsets of CD4 cells
which produce distinct cytokine patterns, Th 1 cells produce IL-2, IFNy, and TNF(3
promoting cellular responses while Th2 cells produce IL-4, IL-5, IL-6 and IL-13 and
support antibody production.
The immunoregulatory role of the Th2 cytokines led to a proposal that these cells may
be beneficial in achieving long term graft survival. Experimental models of
transplantation have indeed shown a predominance of Th2 cytokines in long term
graft survival. However other studies involving abrogation of the co-stimulatory
pathways by CTLA4-Ig or anti-CD40 ligand have shown a reduction in both Thl and
Th2 cytokines (Krams and Martinez, 1998)
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In the case of human liver transplant rejection, several investigators have studied
intra-graft cytokine levels in grafts with and without acute rejection. These have
shown differing results. Some investigators have found an increase in the TH1 type
cytokines IL-2 and IFNy (Bishop et al, 1990 and Gorcynczki et ah, 1994) while others
have found little or no increase in IL-2 (Martinez et al.,1992; Conti et al., 1999). The
TH2 type cytokines IL-4 and IL-5 were found to be increased during rejection by
Martinez (1992) and Conti (1999). Interleukin-10 which has more of an
immunoregulatory role has not been found to be increased in serum or in the graft at
times of rejection (Conti et al, 1999) . The pro-inflammatory TNF-a has been found to
be increased during rejection in the graft with infiltrating monocytes being the major
source( Hoffmann et al., 1993) and other workers have found this cytokine to be
increased in the serum at times of rejection (Imagawa et al., 1991 ;Kita et al., 1996).
These findings are consistent with the development of multiple, concomitant cellular
pathways of immune-mediated injury to the liver.
6. IMMUNOSUPPRESSION
The efficacy of immunosuppressive agents has largely been responsible for the
improvement in outcome of orthotopic liver transplantation. There are many different
regimens combining agents used throughout the world. Some units use antibody
induction therapy with a delayed introduction of calcineurin inhibitor i.e. cyclosporin
or tacrolimus. Almost all regimens would include one of the calcineurin inhibitors.
The other immunosuppressants commonly used are azathioprine and a glucocorticoid,
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in particular prednisolone. Newer agents include mycophenylate mofetil and
rapamycin.
6.1 INDUCTION THERAPY
The use of polyclonal antilymphocyte serum began in 1963 and since that time
several antibody preparations have been developed and used. Antithymocyte globulin
(ATG) and anti-CD3 antibody (OKT3) have been the principal therapies used but
have failed to show superior outcome compared with triple therapies with
cyclosporin, prednisolone and azathioprine. One of the reasons for this was an
increase in infectious complications and post transplant lymphoproliferative disorder
(PTLD) (McDiarmid et al,l 991). In recent years there has been an interest in more
selective monoclonal antibodies which are directed against the IL-2 receptor and do
not appear to increase the incidence ofPTLD (Jonas et al., 1997). Studies using these
newer agents have shown a low incidence of acute rejection but no difference in graft
survival (Langrehr et al., 1997; Nashan, 1996).
6.2 CYCLOSPORIN
The introduction of this naturally occurring lipophilic endecapeptide derived from the
fungus Tolypocladium inflatum Gams revolutionised solid organ transplantation.
Cyclosporin binds to cyclophilin within the cytoplasm of cells and this complex binds
to calcineurin preventing the dephosphorylation of nuclear factor of activated T cells
(NFAT). This nuclear factor is responsible for stimulating the transcription ofmany
genes. Its inhibition therefore reduces the transcription of certain cytokines, in
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particular interleukin 2, which leads to a reduction in the activation and expansion of
T cells (Andus and Lafferty, 1982).
Adverse effects are common and in the large multicentre studies in the United States
and Europe as many as 40% of patients experienced headache and insomnia. A
similar percentage developed hypertension and gastrointestinal symptoms. Renal
impairment occurred in 20-40% of patients in the first 12 months (Henry, 1999). End-
stage renal failure does occur as a result of cyclosporin therapy (Fisher et al., 1997).
New onset renal impairment occurs in only 1-2% after 2 years of treatment (Roberts
et al., 1998). In 5 years of follow up malignancies occurred in 7.2% of patients on
cyclosporin (Wiesner et al., 1998).
The predisposition to infection is difficult to quantify exactly but around 20 %
developed urinary tract infections in the first year. The other common adverse effects
seen with cyclosporin are gingival hypertrophy and hirsutism.
6.3 TACROLIMUS
This macrolide derived from the fungus Tsudakalemide was introduced to clinical
practice in 1987. It is similar in its action to cyclosporin although 10-100 times more
potent.
The adverse effects are similar but not identical to cyclosporin. Tremor and alopecia
occur more frequently with tacrolimus, as does new onset diabetes mellitus (19%).
Diabetes was reversible in half of the patients with either a reduction in dose or
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discontinuation of the drug. Malignancies occurred in 6.4% of patients in a 5 year
study period.
Comparisons between the two calcineurin inhibitors have been made in two large
multicentre trials which compared the Sandimmune preparation of cyclosporin and
tacrolimus (The U.S. multicenter FK506 liver study group, 1994; European FK506
multicentre liver study group, 1994). These studies revealed acute rejection, steroid-
resistant rejection and chronic rejection to be reduced in the tacrolimus group. There
was, however, no difference in the graft and patient survival. The microemulsion
preparation (Neoral) of cyclosporin has replaced Sandimmune, and the doses of
tacrolimus used now have reduced. Therefore the above trials cannot be applied
directly to current practice and the results of the TMC trial comparing Neoral and a
reduced dose of tacrolimus are awaited.
6.4 AZATHIOPRINE
This drug is an imidazole derivative of 6-mercaptopurine and was first used in 1961 in
transplantation. Its mode of action is as an anti-metabolite interfering with cell
division and therefore inhibiting proliferation and differentiation of T cells in
response to antigenic stimulation.
The major adverse effect is bone marrow suppression with leucopenia being more
common and often necessitating a reduction in dosage. The other adverse effects are
gastrointestinal upset, pancreatitis, rash and hepatotoxicity.
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6.5 CORTICOSTEROIDS
These drugs have multiple effects on the immune system and until recently have been
a mainstay of long term immunosuppressive therapy. The principal adverse effects of
corticosteroids are obesity, diabetes mellitus, osteoporosis, hypertension, depression,
cataract and rarely avascular necrosis of the femoral head.
Recently many centres have withdrawn steroid therapy within the first six months.
6.6 MYCOPHENOLATE MOFETIL
This drug inhibits inosine monophosphate dehydrogenase and therefore inhibits the de
novo synthesis of purines (Allison et al, 1994). It has less nephrotoxic effects and may
have a role in sparing calcineurin inhibitor induced adverse effects although no
randomized data is available at present.
A schematic representation of the proposed sites of action of the immunosuppressants
commonly used and the newer agents is shown in Figure 1.4.
27
Figure 1.4. T cell activation and cytokine release leading to clonal expansion and the principal
action of immunosuppressants. ( APC = antigen presenting cell, TCR = T cell receptor, STAT =
signals transducers and activators of transcription, I1-2R = interleukin-2 receptor, NFAT = nuclear
factor of activated T cells, MMF = mycophenolate mofetil)
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7. CONCLUSION AND AIMS
The occurrence of acute cellular rejection is a common event following orthotopic
liver transplantation but this does not appear to adversely affect graft outcome in the
majority of patients. However, severe acute cellular rejection and acute rejection in
patients with hepatitis C infection does adversely affect graft outcome. The benefit of
identifying patients of increased risk of severe acute rejection would therefore be to
monitor their immunosuppression carefully to ensure it is adequate.
The adverse effects of immunosupppressants are multiple both in the early post¬
operative period and later on. The major early complication of transplantation related
to immunosuppression is infection, which has significant morbidity and mortality.
Recent evidence also suggests that early immunosuppressant levels influence chronic
renal impairment (Fisher et al., 1998). In patients with a low risk of acute rejection
there may be scope to reduce initial immunosuppression to prevent infection and
possibly prevent problems with renal function in the longer-term. One would also
expect a reduction in de novo malignancies in the longer term if there was a reduction
in immunosuppression.
The purpose of this thesis was to investigate predictors of acute rejection pre-
transplant in the hope that this information could be used in the future to vary
immunosuppresion on an individual basis depending on the individual's predicted risk
of acute rejection. The influence of clinical and nutritional parameters, cytokine
polymorphisms, stimulated cytokine production and contact sensitisation to a neo-
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antigen was investigated in the recipient. The effect of recipient pre-formed antibodies
to donor cells was also investigated.
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CHAPTER TWO











Acute cellular rejection is common following orthotopic liver transplantation, usually
occurring in the first three weeks following transplantation. There is an increase in
morbidity associated with acute cellular rejection (Fisher et al, 1995), although more
recent reports suggest that a single episode of acute rejection may well improve graft
outcome (Wiesner et al, 1998; Avollo et al, 1998). Most, if not all centres, administer
a protocol immunosuppression regimen to all recipients with adjustments made only
for weight and with the same target levels for calcineurin inhibitors for all recipients.
The adverse effects of immunosuppression are multiple both in the short and longer
term. It may be appropriate to tailor immunosuppression on an individual basis as all
patients are not at the same risk of developing acute rejection.
Retrospective studies have shown original disease to be important in the occurrence of
acute rejection (Farges et al.,1996;Berlakovich et al, 1996;Wiesner et al, 1997;
Adams et al., 1993). More recent reports have suggested other risk factors such as
race, age of the recipient, serum creatinine, presence of oedema and HLA-DR
mismatch (Wiesner et al, 1998). Late acute rejection has been associated with viral
infection and with sub-therapeutic levels of immunosuppression. The aim of this
study was to investigate markers of immune status pre-transplantation in patients with





The case notes and dietetic records of 121 consecutive patients transplanted between
November 1992 and April 1997 receiving their first hepatic allograft were examined
for the following information- sex, aetiology of liver disease, age at liver
transplantation, Child's group, triceps skin fold thickness and mid-arm muscle
circumference, preoperative albumin, creatinine and lymphocyte levels. Nutritional
parameters were compared with normal values for age and sex and classified as
depleted if they were below the 5th percentile and marginal if between the 5th and
15th percentile (Bishop et al, 1981). Other factors investigated were donor age, cold
ischaemia time and number ofHLA DR mismatches between donor and recipient and
T cell lymphocytotoxic crossmatch. HLA typing was carried out at the Scottish Blood
Transfusion service tissue typing laboratory using standard techniques (only 81
recipient/donor types were available). The lymphocytotoxic test was performed in the
same laboratory using standard NIH techniques. Mean follow up was 36 (1-60)
months.
Acute cellular rejection was defined as rejection requiring treatment with high dose
steroids. Most patients (80%) had a protocol biopsy around seven days, although this
was dropped from the protocol for one year. Indications for liver biopsy at other times
were abnormal liver enzymes or slowly resolving liver function tests following
rejection therapy. All patients with acute rejection except one had a biopsy before
treatment was commenced. Acute rejection was graded as mild, moderate or severe
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according to the rejection activity index (Demetris et al., 1997). Late acute rejection
was defined as occurring after the first 30 days.
Immunosuppression was with triple therapy consisting of cyclosporine (lOmg/kg/day)
or tacrolimus (O.lmg/kg/day), azathioprine (2mg/kg/day) and
prednisolone(20mg/day). The target trough levels were 175-200 mmol/1 for the first 6
months, 125-150 mmol/1 for 6-12 months and then 100-125 mmol/ml. Cyclosporin
was initially given intravenously, beginning within the first 6 hours post-transplant for
the first 48 hours, until the microemulsion preparation (1995) became available when
it was then given via a nasogastric tube. Tacrolimus was used in 5 patients (randomly
assigned as part of a clinical trial) with target levels of 10-15ng/l for the first 3 months
and then 5-10ng/l.
2.2 STATISTICAL ANALYSIS
The numerical variables were assessed using student's t-test for the difference
between two means. The existence of an association between acute rejection and
specific categorical variables was verified by use of Chi-square tests. Those
categorical or numerical variables significantly associated with acute rejection were
tested on multivariate analysis using a stepwise approach. All statistical tests were
performed by means of the SPSS statistical software package, release 9.0.0 (1998).
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3.RESULTS
Acute cellular rejection required treatment in 64 (53%) of 121 patients. The severity
of these episodes is shown in table 2.1. Nineteen patients (15%) had more than one
episode of acute rejection treated. Nine of these patients required a second course of
methylprednisolone within two weeks of the initial early rejection episode. Two of
these patients went on to receive OKT3. One patient with two episodes of acute
rejection developed chronic rejection. Five patients had 3 or more episodes of acute
rejection requiring treatment, 4 ofwhom went on to lose their graft from chronic
rejection. Eighteen (95%) of these patients were female (p=0.007) and 4 of the five
patients with a positive crossmatch had recurrent early rejection. No other variable
was significantly different in the group with recurrent rejection as shown in table 2.2.
Eleven patients had an episode of late acute rejection - 5 of which were associated
with immunosuppresive levels below target levels, three at the time ofCMV infection
and 3 with no known attributable factor. The histological severity of these lesions was
mild in 4 patients and moderate in 7 patients. One of these patients has developed
chronic rejection resulting from poor compliance.
Eight (7%) patients developed chronic rejection. All patients were female (p=0.04).
The mean age of patients with chronic rejection was 47.5 +/- 5.2 (S.E.) compared
with 47.6 +/- 1.2 (p=0.34) of patients without chronic rejection. There was no
difference between the two groups in the variables measured including aetiology,
CMV infection, HLA DR mismatch or initial severity of acute rejection (table 2.3).
Patients who had recurrent (5 out of 19) or late rejection (2 out of 11) were more
likely (p=0.03) to develop chronic rejection than those who had a single episode of
early acute rejection (1 out of 34).
The occurrence of acute rejection related to original disease is shown in table 2.4.
Patients with alcoholic liver disease had less acute rejection than patients with non¬
alcoholic liver disease (p=0.01). Patients with chronic viral disease (3 HCV,1 HBV)
were grouped together as there has been no difference in acute rejection rates between
patients transplanted for chronic HBV or HCV infection in our experience.
Table 2.5 shows recipient age, preoperative albumin levels, lymphocyte counts, and
the cold ischaemia time . The patients with acute cellular rejection were younger than
those without (p=0.007). The occurrence of acute rejection with respect to recipient
sex, donor age, serum creatinine pre-transplant and the number ofHLA DR
mismatches is shown in table 2.6. Patients in Childs group A had more acute rejection
than those in groups B and C (p=0.04). Median ages were used for grouping.
Nutritional parameters of patients with chronic liver disease as measured by
anthropometry (n=75), shown in table 2.7, did predict less acute rejection in those
patients who had depleted mid-arm muscle circumference (p=0.01).
Stepwise logistic regression analysis of those variables found to be significant on
univariate analysis indicated that mid-arm muscle circumference was the only factor
independently associated with acute rejection (p=0.01). Patients with a depleted mid-
arm muscle circumference suffered less rejection.
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TABLE 2.1. Histologic severity of acute rejection on day 7 biopsy (n=93, as not all
patients had day 7 biopsy) in recipients with no treatment, early and recurrent acute
rejection.
No rejection Mild Moderate Severe
No treatment 5 31 6 0
Single epsiode of acute rejection 2 22 8
Recurrent episodes of acute rejection 0 13 6
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Table 2.2. Characteristics of recipients developing recurrent rejection.
Single episode Recurrent reiection
Gender - male 14 1
female* 20 18






Child-Pugh class - A 6 2
B 6 7
C 16 6
MAMC - normal 15 8
marginal 5 1
deplete 3 2
TSF normal 9 3
marginal 2 3
deplete 12 5







p = 0.007, x2test
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Table 2.3. The occurrence of chronic rejection.
No chronic rejection Chronic rejection
Gender - male 39 0
female* 74 8
Aetiology- PBC 44 5
non-PBC 69 3







single- early 33 1





* p< 0.05, x2 test
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Primary biliary cirrhosis 24 25
Alcoholic liver disease 14 4
Primary sclerosing cholangitis 6 8
Chronic viral disease 2 2
Autoimmune hepatitis 1 5
Cryptogenic cirrhosis 2 3
Paracetamol induced acute liver failure 5 7
Non A-E acute liver failure 3 4
Others 0 6
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TABLE 2.5.The occurrence of acute rejection related to age at transplantation and
pre-operative levels of albumin and lymphocytes, and cold ischaemia time.
Variable (mean +/- se) No rejection Acute rejection Significance
Age (yrs) 51.3 (1.44) 44.3 (1.66) p - 0.007
Albumin (g/1) 30.2 (0.77) 31.8(0.76) p = 0.59
Lymphocyte count (xlO9) 1.26 (0.10) 1.41 (0.12) p = 0.22
Cold ischaemia time (hrs) 10.6(0.4) 10.6(0.4) p = 0.30
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TABLE 2.6.Sex, donor age, HLA DR mismatches, Child's group and pre-transplant




female 37 45 p=0.53
male 20 19
Donor age
<41 26 32 p=0.75
>41 28 31
HLA DR mismatches




Positive 1 4 p=0.39
Negative 39 43
Severity of liver disease
ALF 8 12 p=0.04
Child-Pugh A 1 9
Child-Pugh B 17 15
Child-Pugh C 31 28
Pre-transplant creatinine(pmol/l)
<160 41 58 p=0.13
>160 13 9
Note: Cut-off value for donor age =median value. Creatinine cut-off to allow
comparison with other published data (Wiesner et al., 1998)
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marginal depletion 5 8 p=0.01
deplete 18 6
Significance by % test.
4.DISCUSSI0N
The occurrence of acute cellular rejection in 53% of patients is in keeping with other
reported series. Recent evidence suggests that a single episode of acute cellular
rejection does not adversely affect graft outcome (Wiesner et al, 1998; Dousset et al.,
1998). However the use of immunosuppressive agents is not without its problems,
with infection being the main early complication, and recent evidence suggesting that
early levels of cyclosporin are predictive of late renal failure (Fisher et al, 1998). The
value of predicting acute cellular rejection may therefore be twofold. On the one hand
those more likely to suffer from acute rejection could have their levels of
immunosuppressants kept at the present accepted levels but those predicted to be less
likely to suffer from acute rejection could receive reduced immunosuppression.
Acute rejection is principally a T lymphocyte mediated response and therefore the
parameters investigated were principally those known to affect cell mediated
immunity, as well as a few others which have been suggested to influence the
incidence of acute rejection. The finding that the cold ischaemia time was not
different between the rejection and non-rejection groups is contrary to Wiesner et al.
(1998) although the longest cold ischaemia time in our group was 15 hours. In the
above study the incidence of acute rejection was increased in grafts with a cold
ischaemia time longer than 15 hours. Other centres have also found no increase in
rejection associated with cold ischaemia time (Shackleton et al., 1995).
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The role ofHLA mismatching in acute cellular rejection is not clear. Many centres,
like ours, have found no association with DR mismatches (Donaldson et al, 1993;
Chen et al., 1994) but this is not every centre's experience (Wiesner et al., 1998). The
role of a positive lymphocytotoxic crossmatch is discussed in a later chapter with a
larger number of patients.
The finding that acute cellular rejection is more likely in younger patients is not
surprising, as cell-mediated immunity is known to decrease with age (Goodwin et al.,
1982; Dworsky et al., 1983). Similarly the finding that severity of liver disease is
related to the incidence of rejection is not unexpected, as cell mediated reactivity has
been shown to be related to severity of liver disease (Zipprich et al., 1982; Konigstedt
et al., 1986).
The influence of original disease has been known for some time and other authors
have noted a reduction in acute cellular rejection in alcoholic liver disease compared
with primary biliary cirrhosis or with non-alcoholic liver disease (Farges et al, 1996;
Berlakovich et al., 1996; Wiesner et al, 1997). A study from Birmingham also found a
reduction in acute rejection in patients transplanted for hepatitis B infection (Adams et
al., 1991). A proposed reason for this may be that patients with alcoholic cirrhosis are
often severely compromised nutritionally, although recent evidence suggests that the
degree of nutritional disturbance is related to severity of disease rather than to
aetiology (Caregaro et al., 1996). The reduced acute rejection reported in hepatitis B
infection may reflect the immune status of the recipient as this infection is thought to
exist in a chronic state in those with impaired cell mediated immunity (Adams and
Neuberger, 1998).
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The effect of renal impairment on cell-mediated immunity in chronic liver disease has
not been investigated. Renal impairment per se does affect cell-mediated immunity as
measured by skin testing (Giacchino et al., 1982) and may have clinical implications
(Kelly, 1996). One previous report (Wiesner et al., 1998) has suggested that liver
patients with higher creatinine pre-transplant are less susceptible to acute rejection
following transplantation. This data although showing the same trend do not show
statistical significance. Serum creatinine is not a reliable indicator of creatinine
clearance and it may be that this is a more potent predictor of impaired cell-mediated
immunity.
An involvement of nutritional status in cell-mediated immunity has been proposed for
some time (Neumann et al, 1976; McMurray et al., 1981). Mid-arm muscle
circumference pre-transplant in this study was the only independent predictor of acute
cellular rejection. This may reflect a relative inability to mount a cell-mediated
response to foreign antigen in patients with protein energy malnutrition. Infection
following transplantation has been found by some to cause a significant difference in
survival in those with a poor nutritional state (Selberg et al., 1997). Fat stores as
measured by triceps skinfold thickness do not appear to reflect immune capabilities to
the same extent.
Chronic rejection is now uncommon and in our small experience the only risk factors
identified were female sex and recurrent acute cellular rejection. The latter risk factor
has been found in other centres (Candinas et al, 1995). Cytomegalovirus infection has
been found to be a risk factor in some centres (O'Grady et al., 1988; Arnold et al,
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1992; Candinas et al., 1995; Evans et al.,2000). It was the policy of our unit to
transplant CMV negative recipients with CMV negative donor livers until 1997 which
may account for this not being a risk factor in our group, as infection was rare.
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5.CONCLUSIONS
Acute cellular rejection requiring treatment is significantly associated with recipient
age, severity of liver disease and mid-arm muscle circumference. Acute rejection
occurs less frequently in recipients transplanted for alcoholic liver disease.
Recurrent acute cellular rejection occurs more frequently in females and is
significantly associated with the development of chronic rejection.
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CHAPTER THREE
THE INFLUENCE OF A POSITIVE LYMPOHCYTOTOXIC












In the early days of solid organ transplantation it became apparent that a positive
lymphocytotoxic crossmatch was associated with hyperacute rejection of renal
allografts (Kissmeyer-Nielsen et ah, 1966; Patel and Teraski, 1969). The mechanism
of hyperacute rejection is dependent on complement damage following the
combination of donor antibody and recipient cells. Hepatic allografts appeared to be
resistant to these preformed antibodies and the early reports suggested no adverse
effects on graft rejection or outcome (Iwatsuki et ah, 1984; Krom et al, 1984; Gordon
et ah, 1986; Moore et al, 1987).
However, reports then began to emerge of cases of hyperacute hepatic allograft
rejection (Hanto et ah, 1978; Bird et ah, 1989; Starzl et al., 1989) and subsequent to
this a series of reports indicating poorer graft outcome in those grafts transplanted
against a positive lymphocytotoxic crossmatch (Takaya et al, 1992; Katz et al, 1994;
Nikaein et ah, 1994; Charco et ah,1996). This, however, was not every centre's
experience (Lobo et al, 1995; Donaldson et al., 1995; Goggins et ah, 1996; Fujita et
ah, 1997).
The liver transplant unit in Scotland was initiated in 1992 and like many units
performed liver transplants without reference to cytotoxic donor-specific antibody





During the period from December 1992 to June 1997 145 adult patients received their
first orthotopic liver transplantation. Thirty-three patients were not tested for
lymphocytotoxic antibody against a specific donor for technical reasons. No ABO
blood group incompatible transplant was carried out. Immunosuppression was
commenced within the first 6 hours with intravenous hydrocortisone (lOOmg twice
daily) and azathioprine (2mg/kg/daily). Cyclosporin (5mg/kg/12 hourly) or tacrolimus
(0.05mg/kg/12 hourly) was commenced within the first twenty four hours.
2.2 CROSSMATCH TEST
The recipients' sera obtained immediately before liver transplantation were tested for
cytotoxic antibody against donor lymphocytes using the standard NIH technique.
Donor T-lymphocytes were obtained from lymph nodes and one microlitre of
patient's serum was added for 30 minutes at room temperature. Five microlitres of
rabbit complement were added for an additional 1 hour at room temperature and
ethidium bromide and acridine orange was added to stain cells. The crossmatch test
was interpreted as positive when more than 20% of donor T-lymphocytes were killed
by recipient serum and negative when less than 20 % of cells were killed.
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2.3 ORGAN PRESERVATION
All of the liver allografts were preserved with University ofWisconsin solution.
2.4 FOLLOW UP AND STATISTICS
Acute cellular rejection was defined as clinical, biochemical and histological evidence
of rejection requiring treatment with high dose steroids. Hepatic allografts were
considered to be lost if the recipient died or when the graft was replaced because of
poor or non-function.
Mean follow up was 28 months (12-60 months).
Survival rates were calculated by the method ofKaplan-Meier with Breslow log rank
tests for significance. Statistical comparisons were made by Student's t- test for the
difference between means, chi-square analysis and Fisher's exact test.
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3 .RESULTS
Twelve (10.7%) of the 112 recipients receiving their first hepatic allograft had a
positive antidonor lymphocytotoxic antibody test. One hundred (89.3%) had a
negative crossmatch. The characteristics of these patients are detailed in table 3.1 and
show no statistical differences between the two groups. There was however a
preponderance of females within the positive crossmatch group (82% vs. 59%). In
addition 67% of the positive crossmatch group had autoimmune liver disease (primary
biliary cirrhosis, primary sclerosing cholangitis or auto-immune chronic active
hepatitis) compared with 38% in the negative crossmatch group. The donor factors,
which may be important in graft function, were not different between the positive and
negative crossmatch groups i.e. mean donor age (42.1 vs.43.1), use of
pressors/inotropes (67% vs. 63%), peak aminotransferases (36.0 U/l vs. 40.7 U/l) and
hypernatraemia (150 mmol/1 vs. 147 mmol/1).
Two patients in the positive crossmatch group had not either been pregnant or
received a blood transfusion. Six patients in this group had been pregnant and
received a transfusion.
Figure 3.1 shows the graft survival for those with a positive and a negative
crossmatch. The twelve month graft survival was 58% in the positive crossmatch
group and 81% in the negative group (p= 0.03). The patient 12 month survival was
83% and 90% (p= 0.41) for those with a positive and negative crossmatch.(Figure
3.2)
Three of the 5 grafts lost in the positive crossmatch group were retransplanted in 1-4
days. The other 2 patients died within 5 days. The first had fibrin thrombi within the
lungs and dilatation of the right heart. The second died from sepsis. Within the
negative crossmatch group 4 patients were re-transplanted within 5 days - 3 for
primary non-function and the other for anastomotic hepatic artery thrombosis. The
other 8 early losses were from sepsis (4), cerebral complications (2) or cardiac arrest
at operation (2). The reasons for the other 7 graft losses were death from sepsis (1),
re-transplantation for chronic rejection (4), hepatic artery thrombosis (1) and disease
recurrence (1).
Table 3.2 shows the episodes of acute cellular rejection in both groups in the grafts
that survived greater than 7 days, demonstrating a significant increase of rejection
requiring treatment beyond one dose of high dose steroids in the positive crossmatch
group within the first 30 days.
Table 3.3 shows the outcome of grafts transplanted against a positive crossmatch.
This shows that 3 of the 7 patients with a strongly positive crossmatch lost their graft,
while the remaining patients had a mean of 2.25 rejection episodes compared with 2
graft losses and a mean of 1 rejection episode in the 5 patients with either weakly
positive or positive crossmatches.
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Table 3.1. Details of patients and immunosuppression.
Crossmatch Positive Negative P
No. of grafts 12 100
Age 54.1 (10.2) 47.4(12.9) 0.08
Male/female 2/10 41/59 0.07




PBC 7 33 N.S.
Alcoholic liver disease 1 20 N.S.
P.S.C. 1 9 N.S.
Viral disease 0 4 N.S.
Fulminant hepatic failure 0 18 N.S.
Tumour 1 0 N.S.
Autoimmune hepatitis 1 5 N.S.
Cryptogenic cirrrhosis 1 7 N.S.
Others 0 4 N.S.
cyc= cyclosporin, pred = prednisolone, aza= azathioprine, tacr = tacrolimus














Figure3.1.Grafts rvivalcu vesaccordingtolymph ytotoxicityossmatch( =0.03,l g ranktest).
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Table 3.2. Acute cellular rejection in positive and negative crossmatches.
Crossmatch Positive (n=7) Negative (n=88) P
One episode of acute cellular
rejection
6 (86%) 46(52%) 0.09
More than 1 episode of acute
rejection within 30 days
4 (57%) 4 (5%) 0.0006
Significancec test, x2 test.
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Table 3.3. Outcome of grafts with a positive crossmatch
Patient Cell death Immuno¬
suppression
Graft status Episodes ofACR
requiring therapy
Number 1 41-80% cyc,aza,pre died 48 months 0
Number 2 41-80% cyc,aza,hyd died day 5
Number 3 81-100% nil died day 1
Number 4 21-40% cyc,aza,hyd failed day 1
Number 5 81-100% cyc,aza,pre functioning 27 months 2
Number 6 81-100% cyc,aza,pre functioning 22 months 4
Number 7 81-100% cyc,aza,hyd failed dayl
Number 8 81-100% cyc,aza,hyd functioning 12 months 2
Number 9 21-40% tac,aza,pre functioning 12 months 2
Number 10 81-100% tac,aza,pre functioning 12 months 1
Number 11 81-100% tac,aza,hyd failed day 2
Number 12 21-40% tac,pre failed 7 months 1
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4. DISCUSSION
The results from this study of 112 patients receiving their first hepatic allograft for
either acute or chronic disease revealed an overall graft and patient survival of 78%
and 89%. Initial graft loss was significantly worse where preformed cytotoxic anti-
donor antibodies existed.
In recent years the standard NIH crossmatch has been joined by more sensitive
methodologies in detecting immune reactivity i.e. long incubation NIH assay,
antihuman globulin (AHG) procedure and indirect immunofluorescent flow cytometry
(Kerman, 1994).
The clinical relevance of these procedures in liver transplantation is questionable as
they may be oversensitive, and recent studies using flow cytometry revealed no
impact on graft survival (Talbot et ah, 1995; Goggins et ah, 1996). It may well be that
the liver is able to neutralize antibody in low titre but in some grafts the protective
mechanisms are over whelmed and the antibody persists. The poor outcome of these
patients was reported by Manez et al. (1993).
The data in our study do not distinguish between immunoglobulin M or G antidonor
antibody. There is evidence in primary recipients of renal allografts that IgM
reactivity does not confer an adverse effect on allograft outcome (Iwaki et ah, 1988;
Kerman et al, 1991)). However, in liver transplantation IgM reactivity has been
shown to adversely affect graft outcome albeit less so than IgG reactivity (Katz et ah,
1994).
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The rate of positive crossmatches is similar to other centres, although the studies
reported to date have used different criteria for a positive crossmatch, varying from
greater than 10 % cell death to 50 % cell death.
The poor early outcome of grafts transplanted across a positive crossmatch found in
other centres was confirmed in our population. Of particular interest was the loss of
grafts with so called primary non-function. The pre-perfusion biopsies of these grafts
did not show any architectural abnormalities or steatosis and the donor risk factors for
graft loss were not different between the two groups. The histological findings of
these failed grafts were not dissimilar to those described by Demetris et al. (1992).
The strict criteria which have been suggested by the same group for hyperacute
rejection were not met but it is possible that immunoligical damage contributed to
graft loss.
The findings of acute cellular rejection requiring additional treatment to a single
course ofmethylprednisolone is also interesting. This has been reported by other
groups (Takaya et al., 1991) using standard crossmatching techniques and more
recently by McCarthy et al. (1999) using flow cytometry crossmatching. The reason
for this finding is not entirely clear. It is noteworthy that there were more episodes of
rejection in the strongly positive crossmatch group compared with the less positive
crossmatches and it may well be that the liver cell injury resulting from anti-donor
antibodies results in a clinicopathological syndrome similar to acute cellular rejection.
In support of this is the finding in this study that there is no increase in the incidence
of chronic rejection in our positive crossmatch group as steroid resistant and
relapsing acute cellular rejection have been shown to be more likely to progress to
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chronic rejection (Wiesner, 1999). An early study from the Mayo clinic which used
AHG lymphocytotoxicity testing has suggested an increase in the vanishing bile duct
syndrome (Batts et al., 1988) in patients with a positive crossmatch and this was
supported by findings in other centres (Takaya et al.,1992; Katz et al., 1994). Recent
studies from other centres however failed to find this association (Nikaein et al, 1994;
Charco et al., 1996; Lobo et al., 1995; Donaldson et al., 1995; Goggins et al., 1996).
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5. CONCLUSIONS
The outcome of grafts in patients with a positive crossmatch is worse than those with
a negative crossmatch but the patient survival is not affected. There appears to be an




THE INFLUENCE OF RECIPIENT GENETIC POLYMORPHISMS IN
TUMOUR NECROSIS FACTOR ALPHA, INTERLEUKIN 10 AND
TRANSFORMING GROWTH FACTOR BETA ONE GENES
1. INTRODUCTION














Cytokines play a major role in the inflammation and immune responses which take
place in allorecognition and rejection. There are a number of cytokines that have been
implicated in these responses. The proinflammatory cytokines tumour necrosis factor
alpha (TNF-a) and interleukin 6 (IL-6) can cause endothelial cell activation, up-
regulate cell adhesion molecules and MHC expression as well as recruiting other
immune cells to the site of inflammation (Rink and Kirchner, 1996). Other cytokines
may have a modulatory function such as interleukin 4 (IL-4) and interleukin 10 (IL-
10).
IL-10 inhibits the proliferation of T cells by inhibiting IL-2 production and reducing
the synthesis of proinflammatory cytokines such as TNF-a, IL-6 and IL-10. It also
downregulates surface expression of MHC class II molecules on antigen presenting
cells (Bhol and Ahmed, 1997).
There is evidence for increased production ofTNF-a in patients undergoing acute
cellular rejection following orthotopic liver transplantation in both serial measurement
of serum levels and intra-graft messenger RNA (Imagawa et al., 1990; Martinez et al.,
1992). Other studies have revealed increased intra-graft expression of other pro¬
inflammatory cytokines such as IL-6 (Gorczynki et al, 1996). The measurement of IL-
10 in serum and graft have shown no changes during liver allograft rejection (Bishop
et al., 1993; Conti et al., 1998) although one study suggested an increase prior to
episodes of acute rejection (Platz et al., 1996).
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Transforming growth factor beta one (TGF-pl) is a multifunctional cytokine with
effects on the immune response and tissue healing. It is chemotactic for inflammatory
cells such as monocytes and neutrophils and can inhibit the production ofTNFa from
T and B lymphocytes (Wayne et al., 1994). It is a potent inducer of both the synthesis
and deposition of extra-cellular matrix. In the context of transplantation there has
been interest in the role of TGF-pi in the development of chronic allograft rejection,
which results in fibrosis of the transplanted organ.
The propensity of an individual to develop acute rejection following liver
transplantation is difficult to predict. One possible reason for individual variation
may be differences in cytokine production related to polymorphisms in cytokine
genes.
The aim of this study was to investigate polymorphisms known to affect the
production of cytokines TNF-a (Louis et al., 1998), IL-10 (Turner et al., 1997) and
transforming growth factor betai (TGF-Pi) (Awad et al., 1998) in vitro in a liver
transplant population and the occurrence of allograft rejection. Many other
polymorphisms exist in other cytokine genes but as yet have not been shown to have




Patients were transplanted at the Scottish Liver Transplant Unit between November
1992 and November 1998. All patients were adults receiving primary transplants.
There were no ABO incompatible transplants in this group. Immunosuppression was
with triple therapy consisting of cyclosporin or tacrolimus, azathioprine (l-2mg/kg)
and prednisolone (20mg tapering to 5 mg at three months post transplant).
Acute rejection was defined as rejection treated with high dose corticosteroids based
upon clinical, biochemical and histological evidence- using the accepted Banff
criteria. Chronic rejection was diagnosed histologically - foamy cell arteriopathy
and/or 50% of portal tracts without a bile duct.
2.2 CONTROLS
Cytokine genotypes were also established for healthy Caucasian controls. The number
varies as the original studies of function were carried out at different time points and
more controls had been recruited for the IL-10 functional study.
2.3 CYTOKINE GENOTYPING
DNA extraction
Genomic DNA was obtained from whole blood by phenol extraction and ethanol
precipitation following proteinase K (Boehringer Mannheim) digestion.
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Polymerase chain reaction (PCR)
DNA was amplified using PCR performed on PTC-100 thermal cycler (Genetic
Research Instrumentation Ltd). Each 30 pi reaction mixture contained 2 pi test DNA
(50-200 ng), 50 mM KC1, 10 mM Tris-HCl, 0.1% Triton X-100, 200 pM each dATP,
dCTP, dGTP and dTTP (Gibco BRL), 2.5mM MgCC (except for TGF-P where 1.5
mM MgCf> was used) 0.4 M betaine monohydrate (Sigma), 0.5 pM each primer and
1U Taq polymerase (Gibco BRL). After an initial melting time of 5 min, samples
were subjected to 30 rounds of 95°C for 30 s. and 72°C for 60 s., with a final
extension time of 5 min. at 72°C. Primers used in each reaction and their annealing
temperatures are shown in table 4.1. The amplified products were monitored by
electropheresis on a 2% agarose gel with ethidium bromide (10 mg/1).
Polymorphism analysis (promoter region for TNF-a and IL-10, leader sequence for
TGFpl)
After specific PCR reactions were performed, two 5' biotinylated oligonucleotide
probes (Genosys Biotechnologies Ltd., Pampisford, UK) were used to positively
identify each polymorphism in cytokine gene promoters by a dot blot technique. Two
pi of PCR product was blotted onto Hybond N+ nylon transfer membrane
(Amersham). The double stranded DNA was seperated by treating membranes with
denaturing solution (0.5M NaOH and 1.5M NaCl) for 5 minutes and then neutralising
solution (1.5M NaCl and 0.5M Tris, pH 7.5) for 60s. The membranes were baked in
an oven at 80°C for 10 min and the DNA was immobilised on to membrane by cross-
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linking in a UV Stratalinker (Stratgen) at 120 mJoules. The membranes were
incubated in 50 ml tubes (Falcon, Becton Dickinson) with 10 ml of 5x SSC
hybridisation buffer (where 5x SSC is 0.75M NaCl and 0.075M NaCitrate) with 0.5%
blocking agent (milk powder), 0.1% N-lauryl sarcosine and 0.02% sodium dodecyl
sulphate (SDS) for 30 min at 42.5°C. Following this 400 ng of specific probe, shown
in table 4.2, was added to each tube and allowed to hybridise for 90 min at 42.5°C.
The membranes were washed twice in 5x SSC containing 0.1% SDS for 5 minutes at
room temperature and then stringency washed in lx SSC with 0.1% SDS for 30
minutes at the temperature appropriate for each cytokine. The membranes were
washed for 60 sec. in 0.15 M NaCl and 0.1M Tris buffer, pH7.5 incubated for 30
minutes at room temperature in the same buffer containing 0.5% milk powder as
blocking agent to reduce non-specific binding and then incubated with
streptavidin/horse radish peroxidase conjugate (Amersham) for 30 minutes at room
temperature before detection by chemiluminescence using the ECL system
(Amersham). X-ray films were developed and binding of allele specific probes was
used to determine genotypes.
2.4 STATISTICAL ANALYSIS
Statistical analysis was carried out using Chi squared tests with a value of p< 0.05
deemed as significant. The Bonferroni correction was applied in multiple
comparisons.
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Table 4.1 .Primers and annealing temperatures for cytokine gene polymorphism.
Primer pairs Sequence T(°C)
TGF-Pi sense 5' -CTTCACCAGCTCCATGTCGACAG-3' 60UC
TGF-pi antisense 5 '-ACTGCGCCCTTCTCCCTG-3' 60°C
TNF-a -308 sense 5' -ACTCAACACAGCTTTTCCCTCCA-3' 66UC
TNF-a -308 antisense 5'-TCCTCCCTGCTCCGATTCCG-3' 66UC
IL-10 sense 5' -ATCCAAGACAACACTACTAA-3' 55.5°C
IL-10 antisense 5' -CGAGCTTTAAAAGATAGTTCC-3' 55.5UC


















TNF-a -308 * G
Coding strand
5'-GAGGGGCATGGGGACGG-3' 56°C
























Analysis of genotypes was carried out in 144 patients who received a transplant and
survived more than 30 days. The distribution of the cytokine genotypes in the
different aetiologies and normal controls are shown in tables 4.3-4.6. In primary
sclerosing cholangitis and autoimmune hepatitis there was an increase in the TNF -
308 A (TNF2) allele compared with controls. In primary biliary cirrhosis however
there was an increase in the TNF-308 G allele (TNF1) compared with controls.
No statistical difference was seen in any aetiology with respect to polymorphisms in
the IL-10 gene or in the TGF-(31 gene.
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Table 4.3. Distribution of TNF-a -308 genotypes in different aetiologies and controls.





PBC (n=61) 34(56) 23(38) 4(7) p=0.02
ALD (n=25) 17(68) 6(24) 2(8) n.s.
PSC (n=16) 5(31) 5(31) 6(38) p=0.02
Viral (n=7) 4(57) 3(43) 0 n.s.












Others 1 4 2
9
Significance test, x test.
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Normal controls(n=330) 93(28) 138(42) 99(30)
PBC (n=61) 15(25) 28(46) 18(30)
ALD (n=25) 9(36) 12(48) 4(16)
PSC (n=16) 3(19) 9(56) 4(25)
Viral (n=7) 2(29) 3(42) 2(29)










Others (n=9) 2 1 3








Normal controls 12(11) 46(48) 41(43)
PBC (n=61) 7(12) 34(56) 20(33)
ALD (n=25) 3(11) 7(28) 15(60)
PSC (n=16) 4(25) 6(37) 6(37)
Viral (n=7) 1(14) 5(72) 1(14)










Others 1 3 3
Table 4.6. Distribution of TGF-pi polymorphisms at position +915 in patients and
controls.
Aetiology TGF+915 T/T TGF+915 C/T TGF+915 C/C
Normal controls 10) 19(18) 86(81)
PBC (n=61) 2(3) 7(11) 52(85)
ALD (n=25) 0(0) 4(16) 21(84)
PSC (n=16) 0(0) 3(19) 13(81)
Viral (n=7) 1(14) 1(14) 5(72)










Others 1 0 6
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3.1 ACUTE REJECTION
The overall incidence of acute cellular rejection in this group was 48%. The incidence
of acute rejection in the different aetiologies is shown in table 4.7.
The occurrence of acute rejection in patients with the different TNF-a genotypes is
shown in table 4.8.The results for IL-10 and TGF-Pi genotypes are shown in tables
4.9 and 4.10. There was a significant difference between the rejection and non-
rejection groups with respect to TNF-a -308 genotype. The increased incidence of
acute rejection was in those patients who were homozygous A/A (p< 0.02, Bonferroni
correction). When acute rejection was further classified as a single episode or
recurrent, there was no significant difference between genotypes with recurrent acute
rejection occurring in 6,8 and 2 patients for the genotypes G/G, G/A and A/A,
respectively. Combining TNF-a genotype with IL-10 genotype did not show
significant differences as shown in table 4.11.
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Table 4.7. The occurrence of acute rejection according to aetiology of liver disease.
AETIOLOGY NO REJECTION ACUTE REJECTION
Primary biliary cirrhosis (n=61) 30 31
Alcoholic liver disease (n=25) 17 6
Primary sclerosing cholangitis (n=16) 6 10
Autoimmune hepatitis (n=8) 4 4
Chronic viral hepatitis (n=7) 3 4
Acute liver failure (n=20) 12 8
Others (n=7) 3 4
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Table 4.8. The incidence of acute rejection with respect to TNF-a -308 genotype
TNF-a -308 genotype G/G A/G A/A
No acute rejection 42 30 4
Acute rejection 28 25 15*
*p<0.01 , x2test. (p<0.02 following Bonferroni correction)
Table 4.9. Acute rejection with respect to IL-10 -1082 genotype (not significant,
X2 test)-
IL-10 -1082 genotype A/A A/G G/G
No acute rejection 21 38 16
Acute rejection 16 30 22
Table 4.10. Acute rejection with respect to TGF-pi +869 and +915 genotype ( not
')
significant, % test).
TGFp, +869 genotype TGFp i +915 genotype
C/C C/T T/T C/C C/G G/G
No rejection 8 37 32 1 11 65
Acute rejection 10 34 23 3 9 55
Table 4.11.The combination of different IL-10 and TNFa genotypes and the
occurrence of acute rejection
TNF-a-308 A/A TNF-a-308 G/A TNF--a-308 G/G
IL10-1082 A/A G/A G/G A/A G/A G/G A/A G/A G/G
Acute rejection 2 10 3 6 11 8 8 9 11
No acute rejection 1 1 2 7 14 7 11 24 7
4.DISCUSSION
4.1 AETIOLOGY
The role of cytokines in the aetiology and progression of liver disease is not
completely understood. The data presented in this chapter suggests that there may be
an association between polymorphisms associated with an increase in TNF-a
production and primary sclerosing cholangitis and autoimmune hepatitis. The data
presented here also suggests an association between primary biliary cirrrhosis and the
polymorphism associated with a low production ofTNF-a.
There has been a recent interest in polymorphisms in cytokine genes as some of these
polymorphisms have functional significance. There has been some published work in
primary biliary cirrhosis already suggesting an increase in the polymorphism TNF1
(G at position -308) in those developing endstage disease (Jones et al., 1999),although
this has not been supported by another study from the UK (Gordon et al, 1999 ). In
support of this there is in vitro data showing that production of TNFa from patients
with PBC is less than in controls and patients with PSC (Broome et al., 1992). The
data regarding acute liver failure secondary to paracetamol poisoning and TNF-a
polymorphisms suggests no role for progression of disease (Bernal et al., 1998)
There is work suggesting an increase in TNFa in patients with autoimmune hepatitis
(Hussain et al., 1994; Maggiore et al., 1995) and although the number of patients with
autoimmune hepatitis was small in this study they all possessed at least one TNF2
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allele which is highly significant compared with normal controls and other
aetiologies. This study, however, does not indicate if this is an aetiological
predisposition or an increased propensity to progress to endstage liver disease
requiring assessment for liver transplantation. A recent publication from Cookson et
al. (1999) reported an increase in the TNF2 gene in patients with type 1 autoimmune
hepatitis, although there was no data on progression of disease (Czaja et al., 1999).
The findings relating to primary sclerosing cholangitis are also interesting as the
aetiology of this liver disease is unknown although presumed immunological. The
findings of 65% of patients with the TNF2 allele compared with 38% of controls is
similar to the recent report from the King's college group who found 58% of patients
to possess the TNF2 allele compared with 29% of controls (Bernal et al., 1999). This
group found no correlation between genotype and disease progression or outcome.
This allele may therefore determine susceptibility to PSC as in other autoimmune
diseases. There is also in vitro evidence to suggest that TNFa production from
PBMC is increased in patients with PSC compared with controls (Broome et al,
1992). Primary sclerosing cholangitis occurs often in patients with inflammatory
bowel disease particularly ulcerative colitis. TNF-a polymorphisms have been
investigated in both Crohn's disease and ulcerative colitis with a modest reduction of
the TNF2 allele in Crohn's disease but no difference from controls in ulcerative
colitis (Louis et al,1996;Bouma et al, 1996). It therefore appears that the TNF2 allele
confers susceptibility to PSC and not to inflammatory bowel disease.
The functional significance of the polymorphisms in the interleukin-10 promoter and
the transforming growth factor-p 1 in disease has been supported by studies in
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humans suggesting a relationship between genotype and cytokine levels in
inflammatory bowel disease for the former (Tagore et al., 1998) and fibrotic lung
disease (Awad et al, 1998) for the latter. IL-10 plays an important role in modulating
T cell responses and theoretically the impaired production of IL-10 may allow the
potentially autoreactive T cells to proliferate with a breakdown in peripheral
tolerance. There is data reporting a decrease in IL-10 mRNA in the livers of patients
with PBC and PSC (Mitchell et al.,1997) and also some in vitro data to suggest that T
cells from patients with PBC produce less IL-10 in response to antigen when
compared with controls (Jones et al.,1997. However our finding that there is no
association between PBC and PSC and IL-10 genotype is in support of the published
data (Przemioslo et al., 1999).
TGFpi mRNA has been shown to be increased in cirrhosis of various aetiologies
suggesting a role in fibrogenesis (Bedossa, 1995; Baer et al., 1998). Studies
investigating TGFpi in autoimmune hepatitis have shown an increase at the time of
inflammation but levels have reduced to baseline and were similar to controls
following treatment (Bayer et al, 1998). This study did not identify any difference in
genotype between patients with cirrhosis and normal controls.
4.2 ACUTE REJECTION
Acute rejection following liver transplantation is an unpredictable event which often
requires treatment with an increase in immunosuppression, usually in the form of high
dose corticosteroids.
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The role of polymorphisms in cytokine genes that influence their production is
largely unknown with respect to acute cellular rejection in liver transplantation. This
may have some bearing on future immunosuppressive strategies if there is a relation
between genotype and rejection.
The pro-inflammatory cytokine TNF-a has many effects in the inflammatory process
and there is evidence to suggest that the polymorphism at position -308 in the
promoter region of the gene influences disease. Individuals possessing the so called
TNF2 genotype (-308 A) have been shown to have worse outcome in cerebral malaria
and non-Hodgkins lymphoma (McGuire et al., 1994; Warzocha et al., 1998). The
influence of this polymorphism in rejection of solid organ allografts has been reported
in both kidney and heart transplantation (Sankaran et al., 1999; Turner et al.,1997), the
latter only showing a statistical difference when combined with IL-10 genotype. The
Ncol polymorphism in the TNFa gene, which may influence TNF-a production in
vitro, has recently been reported to have no influence on the occurrence of acute
rejection (Freeman et al, 1999). This polymorphism is not linked to the polymorphism
at position -308. The large increase in relative risk associated with cerebral malaria
(MacGuire et al., 1994) outcome was associated with the homozygous TNF2
genotype, and it may be that this genotype has more of an effect on TNF-a production
than the Ncol polymorphism.
The finding that 79% of patients who were homozygous for TNF2 required treatment
for acute rejection compared with 40% of patients who were homozygous for TNF1
suggests that it may predispose to the occurrence of acute cellular rejection in liver
transplantation. The finding that there was no difference in genotypes in patients with
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recurrent acute rejection may indicate that the initial recipient recognition of donor
antigen is the only response influenced to a sufficient level by TNF-a genotype.
The role of IL-10 in acute cellular rejection is not straightforward. It has many anti¬
inflammatory properties and one may therefore expect that a polymorphism leading to
high production both in vitro (Turner et ah, 1997) and in vivo (Tagore et ah, 1998) may
protect against acute rejection. However the studies investigating IL-10 in acute
rejection in liver transplantation both in the graft and serum have failed to show
differences between grafts with or without rejection. Studies investigating acute renal
allograft rejection have shown increased IL-10 intragraft expression (Xu et al, 1995;
Sutharanthiran and Strom, 1998) and the recent study reporting cytokine genotypes in
renal allografts showed an increase in rejection in the polymorphism associated with
high IL-10 production (Sankaran et ah, 1999). Cardiac allografts in animal studies
have shown an exacerbation of rejection with the addition of IL-10 and the
measurement of intragraft levels of IL-10 in human grafts do not predict acute
rejection (Lagpp et ah, 1996). As already indicated the single study of cytokine
genotyping in heart transplantation has shown that a combination of a genotype
corresponding to high TNFa production and low IL-10 production was associated
with high levels of rejection in the early post transplant period (Turner et ah, 1997).
There was however no reduced rejection in those with the high IL-10 producer
genotype. The effect that IL-10 has on B cells, causing them to proliferate and
increase the humoral response, may be important in renal transplantation and this may
be one of the reasons for the apparent difference in the effect of IL-10 in the rejection
of different organs.
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In this study there is no evidence that IL-10 polymorphisms either alone or in
combination with specific TNF-a polymorphisms influence the occurrence of acute
cellular rejection. There is a widespread belief that acute cellular rejection in hepatic
allografts is different to that in other solid organ allografts as evidenced by the lack of
requirement for HLA matching and the improved outcome of grafts suffering a single
episode of acute rejection (Wiesner et al., 1998; Dousset et ah, 1998). Therefore it may
not be too surprising that the influence of polymorphisms differs between organs.
Transforming growth factor (3 is a cytokine with immunosuppressive and profibrotic
actions. The data presented suggest no influence ofTGFpi genotype on acute
rejection. There is evidence to suggest that in the case of lung allografts there is a
significant effect on graft outcome with respect to lung fibrosis, which is influenced
by TGF-p genotype (Awad et ah, 1998). Chronic rejection of hepatic allografts is not
common and it occurred in less than 5% of this study population. Larger numbers of
patients will be required to determine if TGF-P 1 genotype influences hepatic
allografts in a similar fashion.
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5.CONCLUSIONS
There is an increase in the TNF2 allele in patients who develop endstage liver disease
from primary sclerosing cholangitis and type 1 autoimmune hepatitis compared with
controls. Patients with endstage PBC however have an increase in the TNF1 allele.
There is an increase in acute cellular rejection in patients who are homozygous for the
TNF2 allele. There is no association between acute cellular rejection and
polymorphisms of the interleukin 10 and transforming growth factor (31 genes.
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CHAPTER FIVE
THE EFFECT OF PRE-TRANSPLANT CYTOKINE




2.2 Measurement of tumour necrosis factor alpha












The treatment of choice for end-stage liver disease is orthotopic liver transplantation.
The prevention of acute cellular rejection requires powerful immunosuppression with
the mainstay of treatment provided by the calcineurin inhibitors cyclosporin and
tacrolimus. The principal mechanism of their immunosuppressive action is by the
inhibition of interleukin 2 transcription by preventing the activation of nuclear factor
of activated T cells (NFAT) (Rao et ah, 1997). The effect of these drugs on the
production of other cytokines is largely inhibitory(Ruhlmann and Nordheim, 1997),
although others such as interleukin-6 are enhanced (Murayami et ah, 1994). Moreover
tacrolimus and cyclosporin have differential effects on the production of some
cytokines (Han et ah, 1995; Hutchinson et ah, 1998).
Acute rejection is not an entirely predictable event and the effects of powerful
immunosuppressive agents have multiple adverse effects including acute renal
impairment and increased susceptibility to infection, and in the longer term chronic
renal damage and malignancy. Liver allograft loss is very infrequently a consequence
of rejection, and some patients may well be over-immunosuppressed. The effects of
pre-transplant parameters on acute rejection have recently been reported on (Wiesner
et ah, 1998). Age, severity of liver disease, renal failure and nutritional status have
been shown to influence the occurrence of acute rejection. If pre-transplant
parameters can reliably identify a propensity for rejection it may well allow tailoring
of immunosuppression.
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The role of cytokines in acute cellular rejection following orthotopic liver
transplantation is unclear. There is an increase in pro-inflammatory cytokines such as
tumour necrosis factor alpha (TNF-a) and IL-6 in both graft and serum at the time of
acute cellular rejection (Imagawa et ah, 1990; Gorczynski et ah, 1996; Tilg et
ah, 1990). Interleukin-5 has also been shown to be increased during acute rejection in
the graft (Martinez et ah, 1992). By contrast interleukin-10 appears to be unchanged
at the time of acute rejection.
The pro-inflammatory cytokines TNF-a and interleukin 6 (IL-6) can cause
endothelial cell activation, up-regulate cell adhesion molecules and MHC expression,
as well as recruiting other immune cells to the site of inflammation. Other cytokines
may have a modulatory function such as interleukin 4 (IL-4) and interleukin 10 (IL-
10).
IL-10 inhibits the proliferation of T cells by inhibiting IL-2 production and reducing
the synthesis of pro-inflammatory cytokines such as TNF-a, IL-6 and IL-10. It also
downregulates surface expression ofMHC class II molecules on antigen presenting
cells.
Cytokine production in endstage liver disease varies with aetiology (Simpson et ah,
1997;) and the pre-transplant levels have not been studied with respect to acute
rejection post-transplant. The aim of this study was to investigate the production of
TNF-a and interleukin-10 by patients with end-stage liver disease awaiting
transplantation and explore any relationship with acute cellular rejection. The effect of
different immunosuppressants was also investigated.
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2 MATERIALS AND METHOD
2.1 PATIENTS
All patients were studied while free from sepsis and in a stable condition while on the
waiting list for orthotopic transplantation.
Thirty ml. of heparinised blood was obtained from patients and healthy controls. The
blood was separated on a density gradient (Histopaque, Sigma Chemical Co.,St Louis,
MO) and 0.5 x 106 peripheral blood mononuclear cells cultured in RPMI 1640 ()
supplemented with 10% fetal calf serum (Gibco, Paisley,U.K) with L-glutamine and
streptomycin added to 12 well plates (Iwaki microplate, supplied by Bibby Sterilin,
Stone, UK).
Stock solutions of tacrolimus (gift from Fujisawa) and cyclosporin (Sigma Chemical
Co.,St Louis, MO) were prepared after first dissolving the drug in ethanol according
to the manufacturers instructions.
Dexamethasone (Sigma Chemical Co.,St Louis, MO) was dissolved in sterile water
and stock solutions prepared.
Immunosuppressants were stored at -20° C and thawed just prior to use and added
tolOng andlOOng per ml. final concentrations in duplicate and preincubated for 30
minutes before stimulating with 200ng of Escherichia coli O 111 :B4
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lipopolysaccharide (Sigma Chemical Co., St Louis, MO). Controls did not have any
LPS added. Culture was performed in a 5% CO2 incubator at 37° C.
Supernatants were removed after 20 hours, centrifuged at 2000g for 10 minutes and
stored at -20° C until enzyme-linked immunosorbent assay (ELISA) testing.
2.2 MEASUREMENT OF TUMOUR NECROSIS FACTOR-a
TNF-a levels were measured using an ELISA according to the manufacturers
(Quantikine, R and D systems Europe, Abingdon, UK).
Ninety-six well plates coated with a murine monoclonal antibody which binds TNF-a
in the assay standard or in the supernatants. The bound TNF-a is next revealed by the
use of polyclonal antibody against the TNF-a which is conjugated to horseradish
peroxidase . The bound enzymatic activity is demonstrated by its oxidative action on
the substrate tetramethylbenzidine in the presence of hydrogen peroxide. After the
reaction has been stopped by the addition of sulphuric acid the colouration obtained is
measured at 450nm. The observed optical density is proportional to the concentration
of TNF-a.
Assay protocol
The reconstituted TNF-a standard containing 1 000 pg/ml used to prepare assay
calibrators by performing serial dilution (1:2) with dilution buffer.
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All supernatants to be tested were diluted 1 in 2 with dilution buffer.
Assay procedure:
Antigen fixation: 200pi of test sample (standard or sample) was added with 50pl of
assay diluent to each well. After an incubation of 2 hours at room temperature, 3
successive washes with wash buffer was performed.
Addition ofconjugate: After the last washing cycle , 200pl ofTNFa conjugate was
added to each well. After incubation for 1 hour at room temperature another 3
successive washes were performed.
Addition ofsubstrate: Following the last wash, 200pl of substrate solution
(tetramethylbenzidine and hydrogen peroxide) was added. After an incubation of 20
minutes at room temperature 50pl of 2M sulphuric acid was added to each well.
Plate reading: The optical density of each well was determined within 30 minutes
using a microtitre plate reader set to a wavelength of 450 nm.
Calculation ofresults: The standard curve was obtained using log-log paper. The
average for each standard, control and test sample was obtained for each duplicate
reading. The concentration of TNFa calibrators (pg/ml) was plotted on the x-axis, and
the absorbance values of the samples was used to determine TNFa values. The value
obtained was multiplied by 2 to get the concentration of the test sample.
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2.3 MEASUREMENT OF INTERLEUKIN-10
The measurement of IL-10 levels was carried out using an ELISA (R and D systems),
the principle ofwhich has been outlined above.
Assay protocol
The reconstituted IL-10 standard containing 500pg/ml was used to prepare assay
calibrators by performing serial dilution (1:2) with dilution buffer.
All supernatant samples to be tested were diluted 1 in 5 with dilution buffer.
Assay procedure
Antigen fixation :200pl of standard or ample were added to each well which was
coated with monoclonal antibody against IL-10. After incubation for 2 hours at room
temperature , 4 successive washes were performed with wash buffer.
Addition of conjugate: Following washing 200 pi of polyclonal antibody with
conjugated horseradish peroxidase was added. After incubation for 1 hour at room
temperature washing was performed four times.
Addition of substrate: Following the last wash, 200pl of substrate solution
(tetramethylbenzidine and hydrogen peroxide) was added. After an incubation of 20
minutes at room temperature 50pl of 2M sulphuric acid was added to each well.
Plate reading: The optical density of each well was determined within 30 minutes
using a microtitre plate reader set to a wavelength of 450 nm.
Calculation of results: The standard curve was obtained using log-log paper. The
average for each standard, control and test sample was obtained for each duplicate
reading. The concentration of 11-10 calibrators (pg/ml) was plotted on the x-axis, and
the absorbance values of the samples were used to determine IL-10 values. The values
obtained were multiplied by 5 to get the concentrations of the test samples.
Time course experiments showed maximum production of cytokine after 12 hours,
and concentration curves showed stimulation to be maximal over 20ng of LPS.
Samples from two patients and from a healthy control at different time points showed
a variation in measured levels ofTNF-a of 1-14% (mean 6%) and 3-12% of IL-10
(mean 8%).
2.4 CYTOKINE POLYMORPHISMS
A number of patients had polymorphisms for TNF-a and IL-10 performed at the
University of Manchester as outlined in chapter 4.
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2.5 ACUTE REJECTION
Acute rejection was defined as rejection requiring treatment with high dose
corticosteroids. The diagnosis was made on clinical and histological grounds.
2.6 STATISTICAL ANALYSIS
The sign test was used to compare paired samples of cytokine concentrations. Mann-
Whitney U test was used to compare differences between patients and controls,
patients with and without acute rejection. Analysis of variance (ANOVA) was used to
investigate a difference between aetiologies.
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3.RESULTS
TNF-a was measured in 21 patients ( 9 primary biliary cirrhosis, 6 alcoholic liver
disease, 4 chronic viral disease, 2 cryptogenic cirrhosis) and in 8 healthy controls.
Interleukin-10 was measured in 18 of the above patients (6 primary biliary cirrhosis,6
alcoholic liver disease, 4 chronic viral disease, 2 cryptogenic cirrhosis) and 6 healthy
controls.
3.1 TUMOUR NECROSIS FACTOR ALPHA
The production of tumour necrosis factor alpha (TNF-a) following LPS stimulation of
PBMC in patients (1220 pg/ml ± 130, mean ± SEM) and controls (820 pg/ml ± 190)
following LPS stimulation is shown in table 5.1, and there was no significant
difference. The production of TNF-a pretransplantation was significantly increased in
patients (1575 ± 190) who went on to develop acute cellular rejection requiring
treatment following transplantation compared with patients who did not have rejection
(950 ± 130) as shown in figure 5.1. There were significant differences between
rejectors and non-rejectors in TNFa production with pre-incubation with the
calcineurin inhibitors but not with lOOng of dexamethasone.
A ROC curve for TNFa production and rejection was used to determine cut off values
(area under the curve 0.792, p = 0.02). A contingency table using a cut off value of
TNF production of 1260 pg/ml is shown in table 5.2.The sensitivity was 78%,
specificity 75%, positive predictive value of 0.70 and negative predictive value of
0.81.
The effect of pre-incubation with the different immunosuppressants in the
inhibition/augmentation of TNF-a production is also shown in table 1 and more fully
in figures 5.2-5.5. TNF-a production in patients was significantly inhibited by
dexamethasone but not cyclosporin or tacrolimus (all p values < 0.0001 with respect
to either dose of dexamethasone compared with LPS, both doses of tacrolimus and
both doses of cyclosporin). Dexamethasone lOOng significantly inhibited TNF-a
production more than lOng of dexamethasone (p<0.0001). In normal controls the
production of TNF-a was also significantly inhibited by dexamethasone in a similar
dose dependent manner. However TNF-a production was also inhibited by tacrolimus
lOng (0.008) and lOOng (p=0.04) but not cyclosporin lOng (p=0.18) or lOOng
(p=1.00). The differential effect of immunosuppressants led to significant differences
in TNFa production between patients and controls not seen with LPS alone.
There was no statistical difference in the production ofTNF-a, following LPS
stimulation, in different aetiologies of liver disease (figure 5.6). The mean values
were 1089 ± 200 pg/ml in PBC (n=9), 1315 ± 300 pg/ml in alcoholic liver disease
(n=6), 1530 ± 140 pg/ml in chronic viral disease (n=4) and 890 ± 270 pg/ml in
cryptogenic cirrhosis (n=2). No statistical difference was observed between
aetiologies in the effects of pre-incubation with different immnunosuppresants.
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Table 5.1. Production of TNF-a (pg/ml) in patients with liver disease and normal





LPS alone 1220(130) 820(190)
LPS + tac 1 OOng 1125 (117) 605 (100)*
LPS + tac 1 Ong 1130(106) 590 (125)**
LPS + eye 1OOng 1240 (120) 740 (171)**
LPS + eye 1Ong 1210(130) 733 (184)*
LPS + dex lOOng 540(78) 216(50)*
LPS + dex lOng 715(100) 370 (90)
Control 6(3) 20 (6)
* p< 0.05, **p< 0.01, Mann-Whitney U. Comparison of patients and controls.
Figure 5.1: Production ofTNFa pre-transplant in patients with and without acute cellular
rejection.(rej = rejection (n=9), no rej = no rejection (n=12)
2000
LPS Tac100 Cyc100 Dex100 Tac10 Cyc10 Dex10
*
p < 0.05, ** p < 0.01, Mann-Whitney U .
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Table 2. Contingency table ofTNFa production pretransplant and acute rejection (p
=0.03, Fisher's exact test)
No rejection Acute rejection
TNF-a <1260 pg/ml 9 2
TNF-a >1260 pg/ml 3 7
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Figure 5.3. Percentage inhibition of TNFa production vs LPS alone by different
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* p=0.02, ** p=0.01
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Figure 5.4. Production ofTNF-a following stimulation with LPS by patients and
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Figure 5.5. Production ofTNF-a following stimulation with LPS by patients and controls



































Figure 5.6. Production of TNF-a following stimulation with LPS by patients and
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3.2 INTERLEUKIN-10
The production of interleukin-10 (IL-10) in patients (770 ± 160 pg/ml) and controls
(522 ± 130 pg/ml) following LPS stimulation was similar (table 5.3). Figure 5.7
shows there is no difference in the amount of IL-10 produced pre-transplant in
patients who developed acute rejection (715 ± 200 pg/ml) following transplantation
and those who did not develop rejection (835 ± 260 pg/ml).
The effect of pre-incubation with different immunosuppressants is shown in table 3
and more fully in figures 5.8-5.11. IL-10 production in patients was significantly
inhibited by preincubation with dexamethasone lOOng (p<0.001) and 10 ng
(p<0.001). Dexamethasone lOOng significantly inhibited IL-10 production more than
lOng of dexamethasone (p=0.02). Interleukin-10 production was augmented by pre¬
incubation with tacrolimus lOng and lOOng (p=0.04, p=0.03). Cyclosporin had no
significant effect on production compared with LPS. In healthy controls
dexamethasone inhibited production of IL-10 (p=0.01 for both doses) but there was
no significant difference between the two doses. Neither tacrolimus nor cyclosporin
had a significant effect on the production of IL-10.There was a significant difference
between the levels of IL-10 produced by patients and controls only in the presence of
dexamethasone.
IL-10 production by PBMC following LPS stimulation was similar in different
aetiologies. The mean values were 980 ± 380 in PBC (n=6), 910 ± 340 in alcoholic
liver disease (n=6), 520 ± 90 in chronic viral disease (n=4) and 570 ± 100 in
cryptogenic cirrhosis (n=2). No statistical difference was observed between
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aetiologies in the effects of pre-incubation with different immnunosuppresants (Figure
5.12).
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Table 5.3.Production of IL-10 (pg/ml) in patients with liver disease and normal controls.
Values expressed as mean (SEM).
Patients (n=T8) Control (n=6)
LPS alone 770(160) 522(130)
LPS + tac lOOng 925(157) 535 (135)
LPS + tac lOng 985 (170) 493 (118)
LPS + eye lOOng 721 (159) 509(128)
LPS + eye 1 Ong 705(166) 439(126)
LPS + dex 1 OOng 305 (72) 64 (21)*
LPS + dex lOng 415(120) 90 (35)*
Control 49 (24) 20 (6)
*
p < 0.05, Mann-Whitney U.
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Figure 5.8: Production of IL-10 pre-transplant in patients with and without acute cellular
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Figure 5.9. Percentage inhibition of IL-10 vs LPS alone with different
immunosuppressants in patients (n=18) and controls (n=6). (mean,SEM)






Figure 5.10. Production of IL-10 following stimulation with LPS by patients and controls
with and without pre-incubation with tacrolimus lOOng and lOng.
Controls
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Figure 5.11. Production of IL-10 following stimulation with LPS by patients and
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Figure 5.12. Production of IL-10 following stimulation with LPS by patients and


























Figure 5.13. Production of IL-10 in different aetiologies (PBC=primary biliary cirrhosis,




















The median values of TNF-a and IL-10 produced are shown in tables 5.4 and 5.5.
There was no significant difference between the different polymorphism and
production of the respective cytokine.
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Table 5.4. The production ofTNF-a (pg/ml) following stimulation by LPS in patients
with liver disease according to polymorphism at position -308.
Median (range) TNF-a production (pg/ml)
TNF-a -308 G/G (n=ll) 1280(150-2500)
TNF-a -308 G/A (n=6) 1220 (720-1930)
TNF-a -308 A/A (n=l) 850
126
Table 5.5. The production of IL-10 (pg/ml) following stimulation by LPS in patients with
liver disease according to polymorphism at position -1052.
Median (range) IL-10 production (pg/ml)
IL-10-1082 A/A (n=7) 700 (375-2500)
IL-10-1082 A/G (n=6) 525 (125-1775)
IL-10 -1082 G/G (n=2) 1225 (350-2100)
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4.DISCUSSION
This study demonstrates that the production TNF-a pre-transplant from peripheral
blood mononuclear cells stimulated by LPS is higher in patients who go on to develop
acute cellular rejection. It also demonstrates a difference in response to tacrolimus
and cyclosporin between patients and controls, and a difference between the
immunosuppressants themselves.
The cytokine levels within hepatic allografts suffering acute rejection show
differences from those grafts not undergoing rejection. TNF-a, IL-5 and IL-6
(Imagawa et al., 1990; Gorczynski et al., 1996;Martinez et al., 1992) have been
shown to be increased whereas IL-10 expression was unchanged. The principal source
ofTNF-a is the monocyte/macrophage although many other cells produce this
cytokine. In a study of human liver allograft rejection elevation of plasma TNF-a
levels was seen concomitantly with large numbers ofTNF-a producing monocytes
within the graft (Hoffmann et al., 1993). There is also evidence to suggest that the
principal source ofTNF-a in acute rejection is recipient monocyte-macrophage cells
(Teramoto et al., 1999). The effect of TNFa in the initiation of the rejection process
presumably by activation of endothelial cells and upregulation of the expression of
adhesion factors is further suggested by the improvement of survival seen in models
where monoclonal antibody against TNF-a is administered post transplant (Imagawa
et al., 1991) The finding that TNF-a production pre-transplant is increased in patients
who then develop acute rejection is interesting. The donor liver results in an
alloimmune response the magnitude ofwhich results in either significant or
insignificant acute rejection. TNF-a is involved in this immune/inflammatory reaction
128
and these results suggest that the pre-transplant production capabilities of the
recipients may reflect the propensity for inflammation within the graft.
Interleukin-10 however has more of an immunomodulatory function and studies in
liver transplantation have indicated a reduction or no change in the intragraft levels at
times of acute rejection (Bishop et al., 1993;Conti et ah, 1999). In other solid organ
transplants IL-10 may well exacerbate rejection (Xu et al.,1995) and anti-IL-10
monoclonal antibodies have been shown to improve survival of heart transplants in
animal models ( Li et al., 1998).
The influence of pre-transplant cytokine levels on rejection has been investigated in
renal transplantation with mean levels of y-interferon increased in the group going on
to develop acute rejection (Kaminski et al., 1995). TNF-a however was not measured
in this study. This study suggests that production ofTNF-a below 1260 pg/ml was
good at predicting patients who were less likely to develop rejection requiring
treatment.
There was no difference in TNF-a production between the aetiologies, although our
numbers were small. There are reports in the literature suggesting a difference in
TNF-a production between different aetiologies of liver disease (Muller at al., 1990;
Broome et al., 1992). There is some evidence that as well as the underlying liver
disease affecting TNF-a production there is individual variation in production
determined by genotype (Louis et al., 1998). There are reports in the transplantation
of various solid organs that TNF-a genotype may influence acute rejection with the
polymorphism associated with increased production increased in the rejection groups
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(Turner et al., 1997; Sankaran et al., 1997). No reports of TNF-a production and
polymorphisms of the gene in liver disease have been published although there are
data suggesting an increase in the TNF-2 polymorphism in primary sclerosing
cholangitis (Bernal et al., 1999) and autoimmune hepatitis (Cookson et al.,1999).
In chapter 4 of this thesis data is presented showing an increase in acute rejection in
patients who are homozygous for the TNF2 allele. This allele has been shown to lead
to an increase in TNF-a production in vitro in healthy controls. The data regarding
TNF-a production in this study did not show any correlation with genotype although
only a single patient was homozygous for TNF2 and the total number of patients was
small.
Long term hepatic allograft survival has been greatly enhanced by effective
immunosuppressants such as cyclosporin and tacrolimus. These compounds are
structurally quite different and bind to separate intracellular receptors- cyclosporin to
cyclophilin and tacrolimus to FK506-binding protein 12 . Their major
immunosuppressive effects appear to be through the inhibition of calcineurin, a
phosphatase, by the respective drug-immunophilin complex. There does appear to be
some difference in the effects of these drugs in vitro depending on the cell type used
and the inductor. In the case of cytokine production there are reports of enhanced
production of IL-6 (Murayama et al., 1994), while many other cytokines are inhibited
e.g. IL-10, IL-2, IL-4 and IL-8 (Ruhlmann andNordheim, 1997).
Tumour necrosis factor alpha production is inhibited in-vitro by both cyclosporin and
tacrolimus in cells from healthy individuals although the mode of activation has been
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shown to influence inhibition. Monocytes in one study were not inhibited by
cyclosporin or tacrolimus when activated by LPS (Andersson et ah, 1992), although
this has not been a universal finding (Murayama et al., 1994). The inhibition of TNF-
a production by tacrolimus and cyclosporin is partly through the inhibition of
calcineurin (Staruch et al., 1998). Our results suggest that patients with liver disease
do not reduce production ofTNF-a from PBMC following pre-incubation with
calcineurin inhibitors whereas control patients do. It has been shown that PBMC from
patients with cirrhosis after resting in vitro for 24 hours produce TNF-a levels similar
to healthy controls (Deviere et al., 1990). It may be that this primed state in cirrhotics
overcomes the proposed mechanism of inhibition by calcinuerin inhibitors. The
inhibition ofTNFa production by dexamethasone is likely to be a different
mechanism unaffected by liver disease. Other studies have shown corticosteroids to
be inhibitors of other cytokines with no effect from either cyclosporin or tacrolimus
t
(van Asmuth et al., 1994).
The differential effect of tacrolimus on the production of IL-10 in patients compared
with normal controls and with the other immunosuppresants is interesting. The studies
on the effect on immunosuppressants on interleukin-10 production are conflicting. In
most studies (Blancho et al., 1995; Naora et al., 1995), as in ours, the production is
unchanged although one study did suggest an upregulation (Blancho et al., 1997). The
literature on tacrolimus is similarly conflicting with reports of no effect (Wang et al.,
1993) and an increase in production (Woo et al., 1995). The mechanisms that control
and regulate IL-10 production are still unclear. There are studies reporting the
upregulation of IL-10 production with substance P, IFN-a and IFN-p (Ho et
al., 1996; Schandene et al., 1996; Porrini et al., 1995;) It is of interest that the mouse
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IL-10 gene has shown regulatory motifs in the enhancer region similar to that in the
11-6 enhancer as tacrolimus has been shown to enhance the IL-6 production in human
monocytes. Interleukin-10 has been shown to suppress inflammatory cytokine
production in humans (de Waal et al., 1991). It also downregulates MHC class II
molecule production in monocytes therefore inhibiting proliferative T cell and
cytotoxic T cell responses (Bejerano et al., 1992). It is possible that the effect of
tacrolimus on interlukin-10 production may contribute to the difference in
immunosuppressive capabilities between tacrolimus and cyclosporin.
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5.C0NCLUSI0NS
The pre-transplant level of the pro-inflammatory cytokine TNF-a is increased in the
group of patients who develop acute cellular rejection post-transplant, suggesting that
a patient's "inflammatory" potential may have some influence on their response to the
allograft.
There is enhanced production of interleukin-10 by peripheral blood mononuclear cells
from patients with liver disease in the presence of tacrolimus and a lack of inhibition
ofTNF-a production by cyclosporin and tacrolimus.
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CHAPTER SIX







2.4 Follow up and Statistics
3. RESULTS
3.1 Skin tests






A recent report of pre-transplant parameters of patients which predict subsequent
development of acute rejection identified recipient age, donor age, HLA-DR
mismatch, serum creatinine, aetiology of liver disease and cold ischaemia time as risk
factors (Wiesner at all998). Data presented earlier in this thesis and recently
published largely agreed with these findings (Bathgate et ah, 1999). The acute
rejection of hepatic allografts is principally a T cell mediated response with a
characteristic histological appearance of bile ductulitis, venous endotheliitis and portal
tract inflammation (Snover et ah, 1984). The histological severity of acute rejection
influences the decision to treat as graft outcome is worse following severe rejection
(Wiesner et ah, 1998).
Contact hypersensitivity reactions are T cell mediated responses that are diminished
in liver disease (Pirisi et al, 1997). The aim of this study was to investigate the
relationship between contact sensitisation to a neo-antigen pre-transplant in patients




Diphenylcyclopropenone is an agent used by dermatologists for the treatment of
alopecia areata. Preparation of the diphenylcyclopropenone was carried out by the
hospital pharmacy using acetone as the solvent. The solutions were kept at 4° C with
a shelf life of 4 weeks.
2.2 PATIENTS
Consecutive patients with chronic disease listed for orthotopic liver transplantation
between February 1997 and August 1998 were sensitised with lOOpl of 0.1%
diphenylcyclopropenone (University ofNijmengen, Netherlands) applied on a fdter
paper under a 2cm Finn chamber (Epitest Ltd Oy, Tuusula, Finland) to the upper arm
for 48 hours. An elicitation test was applied to the opposite forearm 12 days later with
15pi of diphenylcyclopropenone at concentrations of 0.001%,0.0025%,0.005%,
0.01% and 0.025% placed on 8mm filter paper discs on a strip of Finn chambers
(Epitest Ltd Oy, Tuusula, Finland).The elicitation reaction was recorded by a single
observer to reduce any variation. Each concentration was given a score - erythema
and induration = 1, vesicles = 2, bulla = 3. Figure 6.1 indicates the reactions seen.
The scores for each concentration were summated giving a total score out of 15. The






Figure 6.1. Elicitation reactions.
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Figure 6.2. An elicitation reaction in a patient.
The doses of diphenylcyclopropenone used were established by sensitising healthy
controls with varying concentrations. The final test doses as used above all elicited
skin test scores between 8 and 13 in healthy controls (n=5) with a median age of 35
(range, 32-42).
All transplants were carried out at the Scottish Liver Transplant Unit between April
1997 and December 1998. The immunosuppresion regimen was triple therapy with
either microemulsion cyclosporin lOmg/kg/d or tacrolimus O.lmg/kg/d (target trough
levels were 175-200ng/l for cyclosporin and 10-15 ng/1 for tacrolimus,azathioprine
(2mg/kg) and prednisolone 20mg/d. Tacrolimus or cyclosporin (Neoral)
administration was randomly assigned to patients.
Acute rejection was defined as rejection requiring treatment with high dose
corticosteroids. This decision was based on clinical and histological evidence, and
was made by the clinicians on the unit at the time. These clinicians were blinded to
the skin test score. Protocol biopsies were performed at seven days and further
biopsies performed if liver function tests deteriorated or were slow to improve after
rejection therapy. All biopsies in the first thirty days following transplantation were
assessed. The histologic severity of acute rejection was graded according to the Banff
criteria (Demetris et al., 1997). When more than one allograft biopsy was performed
the most severe degree of rejection was used in analyses.
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Details of the donor age and cold ischaemia time were collected. Recipient age,
aetiology, severity of liver disease and nutritional status (anthropometry assessed by a
single dietician) was noted pre-transplant. Lymphocytotoxicity testing and donor
recipient HLA DR mismatching was performed using standard techniques by the
tissue typing laboratory in our institution. Calcineurin inhibitor levels were collected
for each patient.
Chronic rejection was diagnosed using standard histologic criteria after appropraite
clinical/radiologic exclusions (International panel, 2000). Graft loss was defined as
patient death or re-transplantation.
2.3 CYTOKINE POLYMORPHISMS
Cytokine polymorphisms were analysed as described in Chapter 4.
2.4 FOLLOW UP AND STATISTICS
All patients were followed up for at least one year. Univariate analysis was assessed
by the Students t-test for the difference between means for continuous variables and
Chi square testing with Fisher's exact test where appropriate for categorical variables.
Logistic regression for univariate predictors was carried out using SPSS statistical




Forty one patients were sensitised and had elicitation tests performed. Three patients
were transplanted before the elicitation phase could be completed. The age and
nutritional status of the patients completing testing is shown in table 6.1. Nineteen
patients were responders having a skin test score varying from 1-9. Twenty two
patients had no response. The variation in skin test response in the different
aetiologies is shown in table 6.2.
3.2 CORRELATION WITH REJECTION
Three patients, all non-responders, did not survive to transplantation. 38 patients were
transplanted with the mean length of time from elicitation to transplantation being 58
(SEM 11) days.
Thirty eight biopsies in 31 patients were assessed. Seven patients did not have
biopsies at seven days at the discretion of the clinical team at the time. None of these
7 patients required allograft biopsy in the first 30 days and were regarded as negative
for acute rejection.
Acute rejection requiring treatment occurred in 19 (50%) of 38 patients. Five patients,
all responders, required multiple biopsies (2-4). Three of the 5 had additional therapy
for acute rejection. Table 6.3 shows the occurrence of acute rejection according to
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skin test response, donor and recipient age, cold ischaemia time , HLA DR mismatch,
lymphocytotoxic crossmatch, immunosuppression levels, nutritional status and
severity of liver disease. No difference in rejection was seen according to aetiology of
liver disease. Median values for age and donor age were used as cut-off values.
On univariate analysis skin test reponse (p<0.001), donor age (p=0.05), recipient age (
p=0.05) and primary immunosuppression (p=0.003) were significantly associated
with acute rejection. On multivariate analysis skin test response was the only
independent factor associated with rejection (p=0.02).
Table 6.4 shows the severity of rejection in the different skin test scores using the
original histological assessments which were performed by one of three pathologists.
A fourth pathologist re-scored all the biopsies in order to eliminate inter-observer
variation in scoring. These results are shown in table 6.5. There was no increase in the
score of severity of rejection as assessed by the single pathologist but 6 biopsies were
scored as mild compared with moderate and 6 biopsies were scored as having no
rejection compared with mild rejection.
All patients who required more than a single biopsy in the first 30 days had a skin test
score greater than 1 (Table 6.6).
Two patients died within the first 30 days from sepsis and multi organ failure, both
were non-responders. One graft was lost to chronic rejection at 8 weeks (skin test
score 9) and one was lost to hepatic artery thrombosis at 6 weeks (non-responder). All
other grafts were functioning well at 12 months.
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3.3 CYTOKINE POLYMORPHISMS
Table 6.7 shows the cytokine genotype polymorphisms of the patients who responded
and those who had no response. There was no significant difference for any of the
polymorphisms investigated between responders and non-responders.
Table 6.8 shows the cytokine genotype polymorphisms in those with skin tests greater
than or less than or equal to one. There were no significant differences between the
two groups for any of the polymorphisms investigated.
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Table 6.1. Contact sensitisation response according to age aetiology and mid-arm
muscle circumference (n=41)
Non-responders Responder Significance
Age (mean, SEM) 55.8 (7.6) 46.6(8.9) P= 0.001
Childs class- A 1 1
B 5 11 P = N.S.
C 16 7
MAMC - normal 5 7
marginal 5 2 P=N.S.
deplete 12 9
MAMC = midarm muscle circumference. N.S. = non significant.
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Table 6.2. Skin test score according to aetiology (n=41)






Primary biliary cirrhosis (n=17) 9 4 3 1
Alcoholic liver disease (n=10) 7 3 0 0
Primary sclerosing cholangitis (n=5) 2 0 1 2
Chronic viral hepatitis (n=4) 0 2 2 0
Autoimmune hepatitis (n=2) 2 0 0 0
Cryptogenic cirrhosis (n=3) 2 1 0 0
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Table 6.3. The occurrence of acute rejection. (n=38)
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Significance test = yj test.
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Table 6.4. Skin test and histological severity of rejection (n=31)
Skin test score No rejection Mild rejection Mod. Rejection Sev. rejection
0 3 9 0 0
1-2 0 2 5 1
3-4 0 0 4 1
5-6 0 0 3 0
7-8 0 0 1 2
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Table 6.5. Skin test score and histological severity of rejection as scored by a single
pathologist.(n=31)
Skin test score No rejection Mild rejection Mod rejection Sev. Rejection
0 7 5 0 0
1-2 2 3 2 1
3-4 0 2 2 1
5-6 0 0 3 0
7-8 0 0 1 2
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Table 6.6. Severity of rejection in responders and non-responders (p<0.001).
No rej/mild rejection Mod/severe rejection
Non -responder 12 0
Responder 7 12
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Table 6.7. Contingency table for repeat biopsy (p=0.03, Fisher's exact test).
< 2 biopsies 2 or more biopsies
Skin test <1 24 0
Skin test > 1 9 5
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Table 6.8. Cytokine polymorphisms in responders and non-responders.
TNF-a -308 genotype G/G A/G A/A
No response 11 6 1
Response 12 2 3
IL-10 -1082 genotype A/A A/G G/G
No response 7 8 3
Response 5 9 4
TGFp i+869 genotype TGFPi +915 genotype
C/C C/T T/T C/C C/G G/G
No response 3 7 8 1 2 15
Response 5 10 2 1 0 16
Table 6.9. Cytokine polymorphisms and skin test scores greater than one.
TNF-a -308 genotype G/G A/G A/A
Skin test score <1 15 6 2
Skin test score >1 6 2 2
IL-10 -1082 genotype A/A A/G G/G
Skin test score <1 9 10 4
Skin test score >1 3 7 3
TGF(3i +869 genotype TGFPi +915 genotype
C/C C/T T/T C/C C/G G/G
Skin test score <1 5 9 9 1 2 20
Skin test score >1 3 8 1 1 0 11
4.DISCUSSION
This study demonstrates that the inability to mount an immune response to a contact
neo-antigen predicts those patients who are less likely to develop acute cellular
rejection. It also demonstrates a relationship between magnitude of reaction to the
contact antigen and severity of acute rejection.
The occurrence of acute cellular rejection, unless it is severe, does not detrimentally
affect graft outcome in patients without hepatitis C infection. There is also evidence to
suggest that patients with a single episode of acute rejection have in fact an improved
outcome (Wiesner et al.,1998; Avolio et al, 1998). It may therefore be possible to
reduce immunosuppression in patients with a decreased risk of acute rejection in the
knowledge that should they develop acute rejection as a consequence there is no
evidence to suggest that they will detrimentally affect graft outcome.
Contact sensitisation to a neo-antigen has been investigated in the past in renal
transplantation, with responders being at an increased risk of losing their graft in the
first year (Watson et al., 1980). As already indicated, acute rejection does not have the
same detrimental effect on graft outcome in liver transplantation but the findings of
this study could allow a reduction in immunosuppression in the non-responders.
Skin testing in liver disease has been investigated in the past with an impairment of
contact sensitisation found in primary biliary cirrhosis (Sherlock et al., 1969). Perhaps
surprisingly, this did not appear to be related to bilirubin or histological stage.
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Alcoholic liver disease (Snyder et al., 1978) has also been shown to impair contact
sensitisation, as has fulminant liver failure (O'Keefe et ah, 1980).
The effect of nutrition on contact sensitisation is not clearly established. Studies
investigating sensitisation with dinitrochlorobenzene (DNCB) have shown no
attenuation of responses with lesser degrees ofmalnutrition (Harrison et al, 1975). In
our study there was no significant difference between patients with protein
malnutrition as measured by mid-arm muscle circumference and those with normal
nutrition in their sensitisation. Initially investigators felt that skin testing in
hospitalised patients would help identify patients who may well respond to
intervention, but no study has shown any improvement in outcome following dietary
intervention (Twomey et al., 1982). Skin testing before major surgery has been shown
to predict mortality and sepsis (Meakins et al., 1977; Johnson et al., 1979), although
this has not been every centre's experience (Brown et al., 1982).
The contact sensitisation reaction at a cellular level has not been fully established in
humans. However murine experiments have shown this to be complex, involving
three different subsets of T cells, of which CD4 cells are the effectors (Salerno et
al., 1998). The mechanism of acute rejection is principally the direct recognition of
donor MHC on donor antigen presenting cells by host T cells (Orosz et al.). Studies
investigating the T cells present within the portal tracts in acute cellular rejection in
humans have shown variable results with some investigators finding a predominance
of CD8+ T cells (Ibrahim et al., 1993; Wong et al., 1998) while others have found a
predominance of CD4+ T cells (Dollinger et al., 1998).
The ability of a contact sensitisation reaction to predict those patients less likely to
develop acute early rejection post-transplantation is interesting. The pre-transplant
parameters investigated that affect post transplant rejection have been age, aetiology
of liver disease, preoperative creatinine, severity of liver disease and nutritional status
(Adams et al., 1993;Farges et ah, 1996; Wiesner et ah, 1997; Wiesner et ah, 1998;
Bathgate et ah, 1999). There have been some reports suggesting that cold-ischaemia
time and donor age may also influence acute rejection, although this is not every
centre's experience (Shackleton et ah, 1995). All these parameters were investigated in
our population, and none was found to be as useful as skin testing in predicting those
less likely to suffer acute rejection. The threshold for treatment varies from unit to
unit, with mild acute rejection often not being treated (Dousset et ah, 1993). In
patients without a response to diphenylcyclopropenone, the most severe rejection seen
was mild rejection suggesting there is scope to diminish immunosuppression in these
patients.
The finding of increased severity of acute rejection in patients with high skin test
scores is also interesting. There are reports suggesting that severe acute rejection does
lead to a decrease in graft survival. The number of patients in this study is small but
the one patient who developed chronic rejection had the highest skin test score. The
only other patients who required additional therapy to a single course of
methylprednisolone had skin test scores greater than one. The immunosuppressive
agents used also affected acute rejection in our study. There is evidence to suggest
that tacrolimus is more effective in preventing acute rejection from the two multi¬
centre trials (U.S multicenter FK506 liver study group, 1994; European multicentre
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FK506 liver study group, 1994), although our study involved the new microemulsion
preparation of cyclosporin of which there is less comparative data.
There are studies suggesting an increased suscepitibility to infection in patients with
impaired responses to skin testing. Two of the three patients who died while on the
waiting list died from sepsis and the two patients who died in the first two months
also had infection and multi-organ failure. The potential benefit of reducing
immunosuppression in patients with no response on skin testing may be to reduce the
early problems associated with infection in the post-operative period. There is also
evidence to suggest that the long term renal problems seen with cyclosporin are
influenced by levels in the first 30 days, although this study investigated patients
given the older preparation of cyclosporin.
The finding that there was no relationship between skin test response and cytokine
genotyping is not too surprising. The cell mediated response required for contact
sensitisation as indicated above is complex and will involve many different cytokines
and mediators. It may be that other cytokines such as interferon gamma are important
in this reaction although the literature on diphenylcyclopropenone in humans suggests
that there is an increase in TNF-a (Hoffmann et al., 1995).
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5.CONCLUSION
This study demonstrates that the inability to mount a response to a contact neo-
antigen pre-transplant predicts a reduced likelihood of developing acute cellular
rejection following transplantation. A relationship between skin test scores and






Orthotopic liver transplantation is now the established treatment of choice for end-
stage chronic liver disease. The long-term outcome of patient and graft is excellent for
solid organ transplantation and the loss of grafts to either acute or chronic rejection is
now relatively rare. The present immunosuppressive regimens are very effective and
one of the major advances for the future will be to minimise adverse effects of the
present immunosuppressive agents and to consider new agents with less adverse
effects.
Acute cellular rejection in orthotopic liver transplantation, in most cases, does not
affect graft outcome in the long term and may in fact improve patient survival. The
prevention of acute rejection is therefore not a major priority. However the avoidance
of severe acute rejection and acute rejection in patients with hepatitis C infection is
probably desirable given that these two groups appear to have a worse outcome
(Wiesner et al., 1998). It is unknown if there is some long term immunological benefit
from having an episode of acute rejection or whether allowing patients to develop
acute rejection by reducing immunosuppression improves outcome.
The immunosuppression required to prevent acute rejection does have a downside
both in the short and long term. Infection and renal impairment are frequent early
postoperative complications exacerbated by immunosuppressive agents. There is
evidence that the early postoperative levels of cyclosporin has consequences on late
renal impairment (Fisher et al., 1997). In the longer term, the risk of the development
ofmalignancy both lymphoproliferative and solid organ is also increased by the
immunosuppressive regimens used. Other adverse effects that can seriously affect
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quality of life and are relatively commonly experienced include diabetes mellitus,
gingival hypertrophy, headache and hirsutism.
These factors have led to an interest in attempting to assess pre-transplant an
individual's propensity for developing acute rejection. The largest study in the
literature is by Wiesner et al. (1998) who found recipient age, preoperative creatinine,
donor age, cold ischaemia time and HLA-DR mismatch to be associated with acute
rejection. Other earlier studies had shown aetiology to have some relevance with
patients with alcoholic liver disease and Hepatitis B experiencing less episodes of
rejection (Farges et al., 1996; Berlakovich et al., 1996; Adams et al., 1991).
As the majority of chapters included in this thesis involve the prediction of acute
rejection it must be emphasised that acute rejection in a clinical setting is difficult to
define. For the sake of simplicity throughout the thesis acute rejection requiring
treatment with high dose steroids has been used. This is not the same as histological
acute rejection, as the vast majority of protocol biopsies would show evidence of
some degree of acute rejection. The decision to treat was therefore taken by the
clinical team looking after the transplant unit, which changes weekly and all clinicians
do not have the same threshold for treating acute rejection. The definition of acute
rejection therefore represented everyday practice but it may not reflect the severity of
acute rejection precisely. These issues were addressed in chapters 2 and 7 where
histologic severity was included and revealed that no patients with mild acute
rejection received therapy but not all patients with moderate severity were treated.
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The results of a retrospective analysis of the first 123 patients transplanted at the
Scottish Liver Transplant Unit confirmed that patients who are younger are more
likely to develop acute rejection. Severity of liver disease, mid-arm muscle
circumference and aetiology of liver disease was also found to influence rejection
whereas no affect ofHLA-DR mismatch or cold-ischaemia was found. The geography
of the United Kingdom compared with the United States means that the cold
ischaemia times are different. The patients who appear less likely to develop acute
rejection from this study were older patients, patients with Child's C liver disease,
depleted muscle mass and those transplanted for alcoholic liver disease. This chapter
involved a retrospective analysis, which is not as stringent as collecting data
prospectively. For example, not all of the nutritional data were available reducing the
number of patients that could be assessed for all parameters. The purpose of this
initial chapter was to assess parameters that could be compared with skin testing
where data was collected prospectively.
Chapter 3 addressed the issue of hyperacute rejection and the effect of a positive
lymphocytotoxic crossmatch on acute rejection. Hyperacute rejection is well
described in renal transplantation although reports in orthotopic liver transplantation
are limited to a few cases. The finding in this thesis that patients with a positive
lymphocytotoxic crossmatch have an increase in early graft loss may be related to
damage sustained from preformed antibodies and complement fixation. The numbers
involved are relatively small and again this involved retrospective analysis. The
published literature remains split on the role of a positive lymphocytotoxic
crossmatch and it does seem unlikely that transplants will be stopped or therapy
altered on the basis of a positive crossmatch.
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The influence of a positive lymphocytotoxic crossmatch on acute cellular rejection is
also unclear. As reported in this thesis there appears to be no increased incidence of
acute rejection but an increase in recurrent acute rejection. The lack of crossmatch
results in all patients with recurrent rejection in chapter 2 meant that no relationship
was seen in this larger group and it may well be that the small numbers introduced a
type 2 error. There has however been a further report in abstract form of an increase
in recurrent rejection in patients with a positive flow cytometry crossmatch
(McCarthy et al., 1999) but a further negative study has also been reported(Lang et al.,
1999). The influence of a positive crossmatch on acute cellular rejection is therefore
still unclear despite many studies, suggesting that at most there is only a small effect.
Chapters 4 and 5 explore the role of cytokines in predicting acute rejection. It is
difficult to accept that any single cytokine would be responsible for acute rejection
given the redundancy seen in the cytokine networks. However modulation of the
effect of tumour necrosis factor alpha by inhibiting monoclonal antibody has been
shown to be of benefit in the inflammatory conditions rheumatoid arthritis and
Crohn's disease (Maini et al., 1999; Present et al., 1999). The role of cytokine
polymorphisms in acute rejection at most appears minimal. There does appear to be
an association with the polymorphism commonly called TNF2 when this is
homozygous. The homozygous state is relatively low in the population at large
varying from 0-12% in reported series. The lack of association with severity of
rejection and recurrent rejection suggest that any predilection for acute rejection will
not influence graft outcome. Although the identification of recipient polymorphisms
could be carried out in the pre-transplant period it does appear that this relatively time
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consuming investigation would be of little benefit in allowing tailoring of
immunosuppression.
The role of cytokine polymorphisms in disease susceptibility and progression does
look more promising. The numbers of patients with each aetiology was small but the
findings of the TNF2 allele increase in primary sclerosing cholangitis and
autoimmune hepatitis has been reported with larger series, since this work was done,
by other authors (Cookson et al., 1999). There does appear to be an influence of these
alleles on progression of disease and response to therapy (Czaja et al., 1999) in
keeping with the finding of this allele in a population with end-stage disease.
The measurement of cytokines in peripheral blood may not reflect what is going on
in the liver and we therefore extracted peripheral blood mononuclear cells and
stimulated them lipopolysaccharide, which is a potent stimulator ofmonocytes. In the
acute rejection process inflammatory cells will be stimulated within the liver by
cytokines and other mediators produced in the inflammatory reaction. PBMC
production of cytokines may not reflect exactly what is going on in the liver at the
time of acute rejection. This study was not designed to determine mechanisms of
acute rejection but to identify an individuals "inflammatory potential" when cells
involved in the inflammatory process are stimulated. The finding that TNF-a is
increased pre-transplant in patients who go on to develop acute rejection is in-keeping
with the hypothesis that an individual's propensity to produce this inflammatory
cytokine following a stimulus, in this case with allostimulation, has a bearing on the
severity of the inflammatory reaction seen in acute rejection. However the sensitivity
and specificity in predicting acute rejection do not suggest that this test would be of
benefit in the clinical situation regarding tailoring of immunosuppression.
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Contact sensitisation, however, does appear to accurately predict patients who will not
develop significant acute rejection. The number of patients studied was relatively
small but the results do suggest further study would be appropriate. The test itself is
easy to carry out although slightly inconvenient as it involves either the patient
coming to you or you going to the patient on two occasions to carry out the elicitation
reaction and scoring. It would be possible to let the patient or their spouse read the
test result by giving them photographs of the possible reactions. Given that a test
result of greater than 1 indicated the possibility of troublesome rejection the elicitation
phase could be modified to only include the two strongest concentrations which
would reduce the irritation of a positive reaction in the lower concentrations.
The next step in applying this to clinical practice would be to study a reduction in
immunosuppression in the patients with no elicitation response in the early transplant
period to determine any reduction in adverse effects and also any effect on graft
outcome. The possibilities include using no steroids in patients with no skin test
response given that steroids have a broad immunosuppressive effect and the major
problem initially is with infective complications. Alternatively the dose of calcineurin
inhibitors could be reduced to achieve target trough levels half of the presently
accepted levels. This could potentially improve long-term renal outcome and possibly
reduce early infection.
There is also potential for investigating patients in whom a reduction in
immunosuppresion is desired because of established adverse effects such as renal
impairment or malignancy following transplantation to determine if there is any
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relationship to skin test scores while on immunosuppresion and propensity to develop
acute rejection following a reduction in immunosuppression. The role of
immuosuppression in patients with hepatitis C infection is still unclear but it may be
that skin testing would prove useful in tailoring immunosuppression if recurrence of
hepatitis C merited changes in immunosuppression.
The literature does support a contribution to the acute rejection process by donor
factors. It does make sense that a foreign antigen the size of a liver would have
variable potency in allostimulation. Our study suggests, however, that the recipient's
own immune status is the principal determinant in the early acute rejection process.
The recipient's well being in the post-operative period also has some bearing on the
rejection process. In the final study some of our patients with positive skin tests had
prolonged ITU stays and repeat laparotomies which may be the reason they did not
require treatment for acute rejection. Overall "fitness" may be part of the reason that
patients with acute rejection appear to have a better outcome. The other proposed
explanation for this finding is that a mild to moderate rejection episode leads to a
beneficial immunological effect affecting long term graft outcome.
The aim of this thesis was to investigate the possibility of predicting acute rejection
following transplantation in the pre-transplant period by various measurements of the
recipient's immune status. In the studies performed the best predictor appears to be a
contact sensitisation reaction with a neo-antigen. Further studies will clarify if this
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The Effect of a Positive T-Lymphocytotoxic
Crossmatch on Hepatic Allograft
Survival and Rejection
Andrew J. Bathgate,* Mary McCollt 0. James Garden,* John L. R. Forsythe,*
Krishna K. Madhavan,* and Peter C. Hayes*
The influence of crossmatching in liver transplan¬
tation is still controversial, and at present, our
unit does not alter management according to the
result of standard lymphocytotoxicity testing. This
study retrospectively assessed outcome of grafts
transplanted in the presence of preformed antido-
nor cytotoxic antibody. One hundred twelve pa¬
tients undergoing their first orthotopic liver trans¬
plantation had results available (mean follow-up:
18 months). Twelve patients had a positive cross¬
match and 100 negative. The 1-year graft survival
was 58% in the positive crossmatch group, com¬
pared with 81% in the negative crossmatch group
(P = .02). The 1-year patient survival was 83% in
the positive crossmatch group compared with
90% in the negative group (P= .41). Acute cellular
rejection occurred in 6 of 7 (86%) grafts surviving
more than 7 days in the positive crossmatch
group compared with 46 of 88 (52%) grafts in the
negative group (P = .09). However, episodes of
further acute cellular rejection requiring treat¬
ment occurred in 4 of the 6 grafts in the positive
crossmatch group but in only 4 of the 46 grafts
with a negative crossmatch (P = .0006). The
authors conclude that evidence exists in our
population that preformed antidonor antibodies
adversely affect the outcome of hepatic allografts
but not patient survival.
Copyright © 1998 by theAmerican Association for
the Study ofLiver Diseases
In the early days of solid organ transplantation, itbecame apparent that a positive lymphocyto-
toxic crossmatch was associated with hyperacute
rejection of renal allografts.1'2 Hepatic allografts
appeared to be resistant to these preformed antibod¬
ies, and early reports suggested no adverse effects
on graft rejection or outcome.3'6
Reports of cases of hyperacute hepatic allograft
rejection began to emerge,79 and a subsequent
series of reports indicated poorer graft outcome in
those grafts transplanted against a positive lympho-
cytotoxic crossmatch.10"14 However, this is not
every center's experience.15"18
The liver transplant unit in Scotland was initi¬
ated in 1992 and, like many units, performed liver
transplants without reference to cytotoxic donor-
specific antibody status. We have examined the
role of these antibodies in allograft rejection and
graft survival.
From the *Scottish Liver Transplant Unit and the tScottish
Blood Transfusion Service, Royal Infirmary of Edinburgh, Lauris-
ton Place, Edinburgh, Scotland.
Address reprint requests to Andrew J. Bathgate, MD, Depart¬
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Edinburgh, Scotland EH3 9VIV





During the period from December 1992 to June 1997,
145 adult patients underwent orthotopic liver transplan¬
tation (OLT) for the first time. Thirty-three patients were
not tested for lymphocytotoxic antibody against a spe¬
cific donor for technical reasons. No blood group-
incompatible transplantation was performed. Immuno
suppression was begun within the first 6 hours with
intravenous hydrocortisone (100 mg twice daily) and
azathioprine (2 mg/kg/d). Treatment with cyclosporine
(5 mg/kg every 12 hours) or tacrolimus (0.05 mg/kg
every 12 hours) was begun within the first 24 hours.
Crossmatch Test
The recipients' sera obtained immediately before OLT
were tested for cytotoxic antibody against donor lympho
cytes by use of the standard National Institutes of Health
(NIH) technique. Donor T-lymphocytes were obtained
from lymph nodes, and 1 pL of the patient's serum was
added for 30 minutes at room temperature. Five microli
ters of rabbit complement was added for an additional 1
hour at room temperature, and ethidium bromide and
acridine orange were added to stain cells. The cross
match test was interpreted as positive when more than
20% of donor T-lymphocytes were killed by recipient
serum and negative when fewer than 20% of cells were
killed.
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Organ Preservation
All liver allografts were preserved with University of
Wisconsin solution.
Follow-Up and Statistics
Acute cellular rejection was defined as clinical, biochemi¬
cal, and histologic evidence of rejection requiring treat¬
ment with high doses of steroids. Hepatic allografts were
considered lost if the recipient died or the graft was
replaced because of poor or no function.
Mean follow-up was 18 months (range, 2 to 51
months).
Survival rates were calculated by the Kaplan-Meier
method with Breslow log-rank tests for significance.
Statistical comparisons were made by Student's t test for
the difference between means, chi-squared analysis, and
Fisher's exact test.
Results
Twelve (10.7%) of the 112 recipients who received
first hepatic allografts had positive antidonor lym-
phocytotoxic antibody test results. One hundred
(89.3%) had negative crossmatches. The character¬
istics of these patients are detailed in Table 1 and
show no statistically significant differences be¬
tween the two groups. However, there was a
preponderance of women in the positive-cross-
match group (82% v 59%). In addition, 67% of the
positive-crossmatch group had autoimmune liver
disease, compared with 38% of the negative-
crossmatch group. The donor factors that may be
important in graft function did not differ between
the positive- and negative-crossmatch groups, i.e.,
mean donor age (42.1 v 43.1 years), use of pressors/
inotropes (67% v 63%), peak aminotransferase
level (36.0 v 40.7 U/L), and hypernatremia (150 v
147 mmol/L).
Two patients in the positive-crossmatch group
had not been pregnant or received a blood transfu¬
sion. Six patients in this group had been pregnant
and received a transfusion.
Figure 1 shows the graft survival for those with
positive and a negative crossmatches. The 12-
month graft survival was 58% in the positive-
crossmatch group and 81% in the negative-
crossmatch group (P = .03). Twelve-month patient
survival was 83% and 90% (P = .41) for those with
positive and negative crossmatches.
Three of the 5 patients who lost grafts in the
positive-crossmatch group underwent retransplan-
Table 1. Patients and Immunosuppression
Crossmatch Positive Negative P
No. of grafts 12 100
Age (y) (SEM) 54.1 (10.2) 47.4(12.9) .08
Male/female 2/10 41/59 .07
Cold ischemia time
(h) (SEM) 10.5(3.2) 10.4(2.5) NS




rhosis 7 33 NS
Alcoholic liver dis¬
ease 1 20 NS
Primary sclerosing
cholangitis 1 9 NS
Viral disease 0 4 NS
Fulminant hepatic
failure 0 18 NS
Tumor 1 0 NS
Autoimmune hepa¬
titis 1 5 NS
Cryptogenic cir¬
rhosis 1 7 NS
Other 0 4 NS
*Cyclosporine, prednisolone, azathioprine/tacrolimus,
prednisolone, azathioprine.
tation in 1 to 4 days. The other 2 patients died
within 5 days. The first had fibrin thrombi in the
lungs and dilatation of the right side of the heart,
and the second died of sepsis. In the negative-
crossmatch group, 4 patients underwent retrans-
plantion within 5 days—3 for primary nonfunction
and the other for anastomotic hepatic artery throm¬
bosis. The other eight early losses were from sepsis
(n = 4), cerebral complications (n = 2), or cardiac
arrest during surgery (n = 2). The reason for the
other seven graft losses were death from sepsis
(n = 1), retransplantation for chronic rejection
(n = 4), hepatic artery thrombosis (n = 1), and
disease recurrence (n = 1).
Table 2 shows the episodes of acute cellular
rejection in both groups in the grafts that survived
longer than 7 days, demonstrating a significant
increase in rejection that required treatment with
more than one dose of high-dose steroids in the
positive-crossmatch group.
Table 3 shows the outcome of grafts trans¬
planted against a positive crossmatch. This shows
that 3 of the 7 patients with a strongly positive







Neg. crossmatch Figure 1. One-year graft
survival in patients with
positive (n = 12) and
negative (n = 100) cross¬
matches (P= .02).
crossmatch lost their grafts; the remaining patients
had a mean of 2.25 rejection episodes compared
with two graft losses and a mean of one rejection
episode in the 5 patients with either weakly posi¬
tive or positive crossmatches.
Discussion
The results from our single-center study of 112
patients who received a first hepatic allograft for
either acute or chronic disease showed overall graft
and patient survival of 78% and 89%. Initial graft
loss was significantly worse where preformed cyto¬
toxic antidonor antibodies existed.
In recent years, the standard NIH crossmatch
has been joined by more sensitive methodologies
Table 2. Acute Cellular Rejection in Positive
and Negative Crossmatches
Positive Negative
Crossmatch (n = 7) (n = 88) P
One episode of acute
cellular rejection 6(86%) 46(52%) .09
More than one episode
of acute rejection
within 30 days 4 (57%) 4 (5%) .0006
for detection of immune reactivity, i.e., long-
incubation NIH assay, anti-human globulin (AHG)
procedure, and indirect immunofluorescent flow
cytometry.19
The clinical relevance of these procedures in
liver transplantation is questionable because they
may be oversensitive, and recent studies with flow
cytometry show no impact on graft survival.17'20 It
is possible that the liver is able to neutralize
antibody in low titer, but in some grafts, the
protective mechanisms are overwhelmed and the
antibody persists. The extremely poor outcome of
these patients was shown by Manez et al.21
The data in our study do not distinguish be¬
tween immunoglobulin (Ig) M and G antidonor
antibody. There is evidence in primary recipients of
renal allografts that IgM reactivity does not confer
an adverse effect on allograft outcome.2223 How¬
ever, in liver transplantation, IgM reactivity has
been shown to affect graft outcome adversely, albeit
less so than IgG reactivity.12
Our rate of positive crossmatches is similar to
those of other centers,11"18 although the studies
reported to date have used different criteria for a
positive crossmatch, varying from greater than 10%
cell death to 50% cell death. The preponderance of
women did not quite reach significance, unlike the
results in the study of Charco et al,14 who also used
20% cell death as a positive crossmatch.
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(%) Immunosuppression Graft Status
ACR Requiring
Therapy
1 41-80 eye, aza, pre Patient died at 48 mo 0
2 41-80 eye, aza, hyd Patient died on day 5
3 81-100 None Patient died on day 1
4 21-40 eye, aza, hyd Failed on day 1
5 81-100 eye, aza, pre Functioning at 27 mo 2
6 81-100 eye, aza, pre Functioning at 22 mo 4
7 81-100 eye, aza, hyd Failed on day 1
8 81-100 eye, aza, hyd Functioning at 11 mo 2
9 21-40 tac, aza, pre Functioning at 9 mo 2
10 81-100 tac, aza, pre Functioning at 4 mo 1
11 81-100 tac, aza, hyd Failed on day 2
12 21-40 tac, pre Functioning at 2 mo 1
Abbreviations: ACR, acute cellular rejection; eye, cyclosporine; aza, azathioprine; pre, prednisolone ; hyd, hydrocorti¬
sone; tac, tacrolimus.
The poor early outcome of grafts transplanted
across a positive crossmatch found in other centers
was confirmed in our population. Of particular
interest was the loss of grafts with so-called pri¬
mary nonfunction. The preperfusion biopsy speci¬
mens of these grafts did not show any architectural
abnormalities or steatosis, and the donor risk
factors for graft loss were not different between the
two groups. The histologic findings of these failed
grafts were not dissimilar from those described by
Demetris et al.24 The strict criteria that have been
suggested by the same group for hyperacute rejec¬
tion were not met, but it is possible that immunol-
igic damage contributed to graft loss.
The findings of acute cellular rejection requiring
treatment in addition to a single course of methyl-
prednisolone is also interesting. This has been
reported by other groups,1017 and the reason for
this finding is not entirely clear. There were more
episodes of rejection in the group with strongly
positive crossmatches than in the group with less
positive crossmatches, and it is possible that the
liver cell injury resulting from antidonor antibod¬
ies results in a clinicopathologic syndrome similar
to acute cellular rejection. The finding in this study
of no increase in the incidence of chronic rejection
in our positive-crossmatch group supports this
conclusion because steroid-resistant and relapsing
acute cellular rejection have been shown to be
more likely to progress to chronic rejection.25 An
early study from the Mayo Clinic that used AHG
lymphocytotoxicity testing suggested an increase
in the vanishing bile duct syndrome26 in patients
with a positive crossmatch; this was supported by
findings in other centers.11,12 However, recent stud¬
ies from other centers did not find this associa¬
tion.13-17
Our experience supports the findings of other
groups in the adverse initial outcome of grafts
transplanted against a positive crossmatch. More
recent reports that do not show a detrimental effect
on graft survival have used different immunosup¬
pressive regimens from ours and include high-dose
methylprednisolone and in some cases prostaglan¬
din Ej, which may be beneficial in a positive-
crossmatch situation.27 In view of our findings, it is
possible that we need to consider altering our
treatment of patients who have preformed antido¬
nor antibodies.
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The Prediction ofAcute Cellular Rejection
in Orthotopic Liver Transplantation
Andrew J. Bathgate, Paula Hynd, David Sommerville, and Peter C. Hayes
The occurrence of acute cellular rejection after
orthotopic liver transplantation is common. At
present, no allowance is made in immunosuppres¬
sive regimens for parameters other than weight.
We investigated parameters in 121 consecutive
patients receiving their primary allograft to deter¬
mine if there are pretransplantation factors pre¬
dicting the occurrence of acute cellular rejection
after transplantation. The case notes and dietetic
notes of these patients were reviewed for age at
transplantation, cause of liver disease, preopera¬
tive albumin and creatinine levels, lymphocyte
count, anthropometric measurements, donor age,
HLA DR mismatch, and cold ischemia time. Acute
cellular rejection was more likely to occur in
younger patients, patients with Child's class A
disease, and those with normal midarm muscle
circumference. Acute rejection was increased in
transplant recipients from donors aged younger
than 30 and older than 50 years. Acute cellular
rejection was less likely to occur in patients who
underwent transplantation for alcoholic liver dis¬
ease. Chronic rejection was significantly in¬
creased in women and those patients who experi¬
enced recurrent acute rejection. On multivariate
analysis, the only significant predictor was the
decreased likelihood of acute rejection in patients
with depleted midarm muscle circumference. In
conclusion, it may be possible to individualize
immunosuppressive regimens on the basis of
pretransplantation characteristics.
Copyright© 1999 by the AmericanAssociation for
the Study ofLiver Diseases
Acute cellular rejection is common after ortho¬topic liver transplantation, usually occurring
in the first 3 weeks after transplantation. There is
an increase in morbidity associated with acute
cellular rejection,1 although more recent reports
suggest that a single episode of acute rejection may
improve graft outcome.2 3 Most, if not all, centers
administer a protocol immunosuppression regimen
to all transplant recipients, with adjustments made
only for weight and with the same target levels for
calcineurin inhibitors for all recipients. The ad¬
verse effects of immunosuppression are multiple,
both in the short and longer term. It may be
appropriate to tailor immunosuppression on an
individual basis because all patients do not have
the same risk for developing acute rejection.
Retrospective studies have shown original dis¬
ease to be important in the occurrence of acute
rejection,4"6 and more recent reports have sug¬
gested other risk factors, such as age of the re¬
cipient.3We investigated markers of immune status
pretransplantation in our patients with chronic
liver disease to identify their value in predicting the
risk for developing acute cellular rejection.
Methods
Patients
The case notes and dietetic records of 121 consecutive
patients who underwent transplantation between Novem
ber 1992 and April 1997, receiving their first hepatic
allograft, were examined for the following information:
sex, cause of liver disease, age at liver transplantation,
Child's class, triceps skinfold thickness and midarm
muscle circumference, preoperative albumin and creati¬
nine levels, and lymphocyte counts. Nutritional param¬
eters were compared with normal values for age and sex
and classified as depleted if they were less than the 5th
percentile and marginal if between the 5th and 15th
percentile.7 Other factors investigated were donor age,
cold ischemia time, and number of HLA DR mismatches
between donor and recipient. HLA typing was performed
at the Scottish Blood Transfusion Service Tissue Typing
Laboratory using standard techniques (only 81 recipient/
donor types were available). Mean follow-up was 36
months (range, 1 to 60 months).
Acute cellular rejection was defined as rejection
requiring treatment with high-dose steroids. Most pa¬
tients (83%) had a protocol biopsy performed at approxi
mately 7 days, although this was removed from the
protocol for 1 year. Indications for liver biopsy at other
times were abnormal liver enzyme levels or slowly
resolving liver function test results after rejection therapy.
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Table 1. Severity ofAcute Rejection on Day 7
Biopsy in Patients With No Treatment and Early
and Recurrent Acute Rejection
No
Rejection Mild Moderate Severe
No treatment 5 31 6 0
Single episode
of acute rejec¬
tion — 2 22 8
Recurrent epi¬
sodes of acute
rejection — 0 13 6
All patients with acute rejection except 1 underwent a
biopsy before treatment was commenced. Acute rejec¬
tion was graded as mild, moderate, or severe according to
the rejection activity index.8 Late acute rejection was
defined as occurring after the first 30 days.
Immunosuppression used triple therapy consisting of
cyclosporine (10 mg/kg/d) or tacrolimus (0.1 mg/kg/d),
azathioprine (2 mg/kg/d), and prednisolone (20 mg/d).
The target trough levels were 175 to 200 ng/mL for the
first 6 months, 125 to 150 ng/mL for 6 to 12 months, and
then 100 to 125 ng/mL. Cyclosporine was initially
administered intravenously, beginning within the first 6
hours posttransplantation for the first 48 hours, until the
microemulsion preparation became available (in 1995),
after which it was then administered through a nasogas¬
tric tube. Tacrolimus was used in 5 patients (randomly
assigned), with target levels of 10 to 15 ng/mL for the
first 3 months and then 5 to 10 ng/mL.
Statistical Analysis
The numerical variables were assessed using Students
t-test for the difference between two means. The exis
tence of an association between acute rejection and
specific categorical variables was verified by use of
Pearson's Chi-squared tests. Those categorical or numeri
cal variables significantly associated with acute rejection
were tested on multivariate analysis using a stepwise
approach. All statistical tests were performed by means
of the SPSS statistical software package, release 6.1.3
(1995, SPSS Inc., Chicago).
Results
The overall incidence of acute cellular rejection in
121 patients was 53%. The severity of these epi¬
sodes is shown in Table 1. Nineteen patients (15%)
had more than one episode of acute rejection
treated. Nine of these patients required a second
course of methylprednisolone within 2 weeks of
the initial early rejection episode. Two of these
patients went on to receive OKT3. One patient with
two episodes of acute rejection developed chronic
rejection. Five patients had three or more episodes
of acute rejection requiring treatment, 4 of whom
went on to lose their graft from chronic rejection.
Eighteen of these patients (95%) were women
(P = .007). No other variable was significantly
different in the group with recurrent rejection.
Eleven patients had an episode of late acute
rejection, five of which were associated with immu¬
nosuppression levels less than target levels, three
episodes at the time of cytomegalovirus (CMV)
infection, and three episodes with no known attrib¬
utable factor. The histological severity of these
lesions was mild in 4 patients and moderate in 7
patients. One of these patients developed chronic
rejection resulting from poor compliance.
Eight patients (7%) developed chronic rejec¬
tion. All patients were women (P = .04) aged
47.5 ± 5.2 years (mean ± SE) compared with
47.6 ± 1.2 years (P = .34) for patients without
chronic rejection. There was no difference between
the two groups in the variables measured, includ¬
ing cause of liver disease, CMV infection, HLA DR
mismatch, or initial severity of acute rejection.
Patients who had recurrent (5 of 19 patients) or
late rejection (2 of 11 patients) were more likely
(P = .03) to develop chronic rejection than those
who had a single episode of early acute rejection (1
of 34 patients).
The occurrence of acute rejection related to
original disease is listed in Table 2. Patients with
Table 2. Acute Cellular Rejection in Different
Causes of Liver Disease
No Acute
Cause Rejection Rejection
Primary biliary cirrhosis 24 (20) 25 (21)
Alcoholic liver disease 14(12) 4(3)
Primary sclerosing cholangitis 6(5) 8(7)
Chronic viral disease 2(2) 2(2)
Autoimmune hepatitis 1(1) 5(4)
Cryptogenic cirrhosis 2(2) 3(2)
Paracetamol-induced acute
liver failure 5(4) 7(6)
Non A-E acute liver failure 3(2) 4(3)
Others 0 6(4)
NOTE. Values expressed as number of patients (%).
Abbreviation: Non A-E, NonANon B Non C Non E.
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alcoholic liver disease had less acute rejection than
patients with nonalcoholic liver disease (P = .01).
Table 3 lists recipient age, preoperative albumin
levels, lymphocyte counts, and the cold ischemia
times. The patients with acute cellular rejection
were younger than those without (P = .007). The
occurrence of acute rejection with respect to recipi¬
ent sex, donor age, serum creatinine level pretrans-
plantation, and the number of HLA DR mismatches
is listed in Table 4. Patients with Child's class A
disease had more acute rejection than those with
classes B and C (P = .04).
Nutritional parameters of patients with chronic
liver disease, measured by anthropometry (n = 75),
listed in Table 5, predicted less acute rejection in
those patients who had depleted midarm muscle
circumference (P = .01).
Stepwise logistic regression analysis of those
variables found to be significant on univariate
analysis indicated that midarm muscle circumfer¬
ence was the only factor independently associated
with acute rejection (P = .01).
Discussion
The occurrence of acute cellular rejection in 53% of
the patients is in keeping with other reported
series. Recent evidence suggests that a single epi¬
sode of acute cellular rejection does not adversely
affect graft outcome.2'3 However, the use of immu¬
nosuppressive agents is not without its problems,
with infection as the main early complication and
recent evidence that suggests early levels of cyclos-
porine are the principal predictors of late renal
failure.9 The value of predicting acute cellular
rejection may be twofold. Those more likely to
experience acute rejection could have their levels
Table 4. Sex, DonorAge, HLA DR Mismatches,
Child's Class, and Pretransplantation Creatinine














Severity of liver disease
ALF 8
Child's class A 1
Child's class B 17





Abbreviation: ALF, acute liver failure.
of immunosuppressives maintained at the present
accepted levels, but those predicted to be less likely
to experience acute rejection could reduce immuno¬
suppression.
Acute rejection is principally a T-lymphocyte-
mediated response; therefore, the parameters inves¬
tigated were principally those known to affect
cell-mediated immunity, as well as a few others that
Table 3. The Occurrence of Acute Rejection
Related to Age at Transplantation and Preoperative
Levels ofAlbumin, Creatinine, and Lymphocytes
No Acute
Variable Rejection Rejection P
Age (yr) 51.3 ± 1.44 44.3 + 1.66 .007
Albumin (g/L) 30.2 + 0.77 31.8 ±0.76 .59
Lymphocyte count
(X109) 1.26 ±0.10 1.41 ±0.12 .22
Cold ischemia
time (h) 10.6 ± 0.4 10.6 ±0.4 .30
NOTE. Values expressed as mean ± SE.
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have been suggested to influence the incidence of
acute rejection. The finding that the cold ischemia
time was not different between the rejection and
nonrejection groups is contrary to the results of
Wiesner et al,3 although the longest cold ischemia
time in our group was 15 hours, which was the
time beyond which the incidence of acute rejection
was increased in the study of Wiesner et al.3 The
donor age findings were also different because the
increases in rejection were in the younger and older
donor age groups compared with the donor age
groups of 30 to 39 years in the previous study.
The role of HLA mismatching in acute cellular
rejection is not clear, with many centers such as
ours finding no associationwith DR mismatches,1011
although this is not every centers experience.3
The finding that acute cellular rejection is more
likely to occur in younger patients is not surprising
because cell-mediated immunity is known to de¬
crease with age.1213 Similarly, the finding that
patients with less severe liver disease are more
susceptible to rejection is not unexpected because
cell-mediated reactivity has been related to severity
of liver disease.14'15
The influence oforiginal disease has been known
for some time, and other investigators have noted a
reduction in acute cellular rejection in alcoholic
liver disease compared with primary biliary cirrho¬
sis or nonalcoholic liver disease.4"6 The reason for
this may be that patients with alcoholic cirrhosis
are often severely compromised nutritionally, al¬
though recent evidence suggests that the degree of
nutritional disturbance is related to severity of
disease, rather than cause.16
The effect of renal impairment on cell-mediated
immunity in chronic liver disease has not been
investigated. Renal impairment per se affects cell-
mediated immunity as measured by skin testing17
and may have clinical implications.18 One previous
report3 suggested that liver transplant patients with
greater creatinine levels pretransplantation are less
susceptible to acute rejection after transplantation.
Our data, although showing the same trend, do not
show statistical significance. Serum creatinine level
is not a reliable indicator of creatinine clearance,
which may be a more potent predictor of impaired
cell-mediated immunity. Further studies may con¬
firm this.
An involvement of nutritional status in cell-
mediated immunity has been proposed for some
time.1920 Midarm muscle circumference pretrans¬
plantation in our experience was the only indepen¬
dent predictor of the absence of acute cellular
rejection. This may reflect a relative inability to
mount a cell-mediated response to foreign antigen
in patients with protein energy malnutrition. Infec¬
tion after transplantation has been found by some
to cause a significant difference in survival in those
with a poor nutritional state.21 Fat stores, measured
by triceps skinfold thickness, do not appear to
reflect immune capabilities to the same extent.
Chronic rejection is now uncommon, and in our
small experience, the only risk factors identified
were female sex and recurrent acute cellular rejec¬
tion. The latter risk factor has been found in other
centers.22 CMV infection has been found to be a
risk factor in some centers.22 23 It was the policy of
our unit to transplant CMV-negative patients with
CMV-negative donor livers until 1997, which may
account for this not being a risk factor in our
group, as infection was rare.
The significance of these findings in clinical
practice are unknown, but it may be appropriate to
administer immunosuppression at a lower level in
patients who are muscle depleted, especially if they
are undergoing transplantation for alcoholic liver
disease. It may be that more dynamic tests of
cell-mediated immunity, such as skin testing,24 may
be more helpful in predicting pretransplantation
the patients more or less likely to experience acute
cellular rejection.
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Pretransplantation Tumor Necrosis Factor-a
Production Predicts Acute Rejection After
Liver Transplantation
Andrew J. Bathgate, * Patricia Lee,f Peter C. Hayes,f andKenneth J. Simpson
Immunosuppressive therapy has many adverse effects in
both the short and longer term. Tailoring immunosup¬
pression might be possible if pretransplantation parame¬
ters predicted rejection. We investigated production of
the proinflammatory cytokine, tumor necrosis factor-a
(TNF-a), and the anti-inflammatory cytokine, interleu-
kin-10 (IL-10), pretransplantation to determine whether
there is a relation with acute rejection. Peripheral-blood
mononuclear cells were obtained from patients with
chronic liver disease on thewaiting list for orthotopic liver
transplantation and healthy controls. Cells (0.5 X 10s)
were stimulated with 200 ng of lipopolysaccharide. Pre¬
incubation for 30 minutes with tacrolimus, cyclosporine,
and dexamethasone at concentrations of 10 and 100 ng
was also performed. TNF-o; and IL-10 levels were mea¬
sured by enzyme-linked immunosorbent assay. Acute re¬
jection was defined on clinical and histological grounds.
Pretransplantation in vitro production ofTNF-a signifi¬
cantly (P < .05) increased in the group of patients with
acute rejection (n = 9) compared with those who did not
develop rejection (n — 12). Preincubation with dexameth¬
asone significantly (P < .001) reduced TNF-a and IL-10
production in both patients and controls (n = 8). IL-10
production pretransplantation was not different in those
who developed acute rejection (n = 9) compared with
those who did not (n — 9). Preincubation with tacrolimus
augmented (P < .05) the production of IL-10 in patients
(n = 18), but not controls (n = 6). Pretransplantation
TNF-a production is increased in patients who go on to
develop acute rejection posttransplantion. (Liver Transpl
2000;6:721-727.)
The treatment ofchoice for end-stage liver disease isorthotopic liver transplantation. The prevention
ofacute cellular rejection requires immunosuppression,
with the mainstay of treatment provided by the cal-
cineurin inhibitors, cyclosporine and tacrolimus. The
principal mechanism of their immunosuppressive ac¬
tion is inhibition of interleukin-2 (IL-2) transcription
by preventing the activation of nuclear factor of acti¬
vated T cells.1 The effect of these drugs on the produc¬
tion of other cytokines is largely inhibitory,2 although
some, such as IL-6, have been shown to be enhanced.3
Moreover, tacrolimus and cyclosporine have differen¬
tial effects on the production of some cytokines.4'5
Acute rejection is not an entirely predictable event,
and the powerful immunosuppressive agents have mul¬
tiple adverse effects, including acute renal impairment,
increased susceptibility to infection, and, in the longer
term, chronic renal damage and malignancy. Liver al¬
lograft loss is very infrequently a consequence of rejec¬
tion, and some patients may be overimmunosup-
pressed. The effects of pretransplantation parameters
on acute rejection have recently been reported.6 Age,
severity of liver disease, renal impairment, and original
disease have been shown to influence the occurrence of
acute rejection. If pretransplantation parameters can
reliably identify a propensity for rejection, it may allow
tailoringof immunosuppression for individual patients.
The role ofcytokines in acute cellular rejection after
orthotopic liver transplantation is unclear. There is an
increase in such proinflammatory cytokines as tumor
necrosis factor-a (TNF-a) and IL-6 in both graft and
serum at the time of acute cellular rejection.7"9 Intra-
graft IL-5 levels are also increased during acute rejec¬
tion.10 Conversely, IL-10 levels in serum and graft ap¬
pear to be unchanged at the time ofacute rejection.11'12
The proinflammatory cytokines, TNF-a and IL-6,
can activate endothelial cell and up-regulate cell adhe¬
sion molecules and major histocompatibility complex
(MHC) expression, as well as recruit other immune
cells to the site of inflammation. Other cytokines, such
as IL-4 and IL-10, may have a modulatory function.
IL-10 inhibits the proliferation ofT cells by inhib¬
iting IL-2 production and reducing the synthesis of
such proinflammatory cytokines as TNF-a, IL-6, and
IL-1/3. It also down-regulates surface expression of
MHC class II molecules on antigen-presenting cells.
Cytokine production varies with the cause of end-
stage liver disease,1314 and pretransplantation levels
have not been studied with respect to acute rejection
posttransplantation. The aim of this study was to inves-
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tigate TNF-a and IL-10 production by patients with
end-stage liver disease awaiting transplantation and ex¬
plore their relation with acute cellular rejection. The
effect of different immunosuppressants was also inves¬
tigated. We found increased in vitro production of
TNF-a by patients who developed acute rejection, but
no difference in IL-10 production.
Patients and Methods
Patients
All patients studied were free from sepsis and in a stable
condition while on the waiting list for orthotopic transplan¬
tation (9 women, primary biliary cirrhosis [6 for IL-10 pro¬
duction]; 6 men, alcoholic cirrhosis; 4 men, chronic viral
disease; and 2 women, cryptogenic cirrhosis).
Ethical approval and informed consent were obtained.
Thirty milliliters of heparinized blood was obtained from
patients and healthy controls. Blood was separated on a den¬
sity gradient (Histopaque; Sigma Chemical Co, St Louis,
MO), and 0.5 X 106/mL of peripheral-blood mononuclear
cells (PBMCs) suspended in RPMI 1640 with L-glutamine
(Sigma Chemical Co) supplemented with 10% fetal calf se¬
rum (Gibco, Paisley, UK) and streptomycin was added to
12-well plates (Iwaki microplate, supplied by Bibby Sterilin,
Stone, UK). One milliliter (0.5 X 10f> cells) ofsuspension was
added to each well and placed in a 5% carbon dioxide incu¬
bator at 37°C.
Tacrolimus (agift from Fujisawa Co, Munich, Germany),
cyclosporine (Sigma Chemical Co), and dexamethasone (Sig¬
ma Chemical Co) were added to 10- and 100-ng/mL final
concentrations in duplicate and preincubated for 30 minutes
before stimulating with 200 ng of lipopolysaccharide (LPS)
EscherichiacoliOil 1 :B4 (SigmaChemical Co). Supernatants
were removed after 20 hours and stored at —20°C until cyto¬
kine level measurement.
TNF-a and IL-10 concentrations were determined by
enzyme-linked immunosorbent assay (Quantikine; R&D
Systems Europe, Abingdon, UK) according to the manufac¬
turer's instmctions. Briefly, supernatant was added to 96-well
precoated monoclonal antibody microtiter plates in dupli¬
cate. After incubation for 2 hours, the wells were washed 4
times, and conjugate was added to each well. After incubation
for 1 hour and further washing, substrate was added and
incubated for 30 minutes. Optical density was measured at
450 nm and compared with the standard curve.
Samples obtained at different times pretransplantation in
the same patients showed a variation in measured levels of 1%
to 14% (mean, 6%) for TNF-a and 3% to 12% (mean, 8%)
for IL-10.
Acute rejection was defined as rejection requiring treat¬
mentwith high-dose corticosteroids. The diagnosis was made
on clinical and histological grounds.1,5
Table 1. Occurrence ofAcute Rejection According to




Primary biliary cirrhosis 3 6








NOTE. Pretransplantation creatinine level not significant.
Statistical Analysis
The sign test was used to compare paired samples ofcytokine
concentrations. Mann-Whitney U test was used to compare
differences between patients and controls; patients with and
without acute rejection. Analysis of variance (ANOVA) was
used to investigate a difference between causes of liver disease.
Results
Acute Rejection
Acute rejection requiring treatment occurred in 9 of 21
patients (43%). The occurrence ofacute rejection with
respect to cause of liver disease, recipient age, and pre¬
transplantation creatinine level is listed in Table 1.
'There was a trend for acute rejection to occur in
younger recipients (P = . 1).
TNF-a
Production ofTNF-a in patients (1,220 ± 130 pg/mL;
mean ± SEM; n = 21) and controls (820 ± 190
pg/mL; n = 8) after LPS stimulation ofPBMCs is listed
in Table 2. There was no significant difference. Produc¬
tion of TNF-a pretransplantation significantly in¬
creased in patients (1,575 ± 190 pg/mL) who went on
to develop acute cellular rejection requiring treatment
after transplantation compared with patients who did
not have rejection (950 ± 130 pg/mL; P = .02; Fig. 1).
TNF-a production remained significantly greater in
patients who developed acute cellular rejection after
preincubation with cyclosporine or tacrolimus, but was
similar with 100 ng of dexamethasone.
The best threshold for TNF-a production was de¬
termined using a receiver operator curve. A contingency
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Table 2. Production ofTNF-a in Patients With Liver
Disease and Healthy Controls
Patients Healthy Controls
(n = 21) (n = 8)
LPS alone 1,220 ± 130 820 ± 190
LPS + tac 100 ng 1,125 ± 117 605 ± 100*t
LPS + tac 10 ng 1,130 ± 106 590 ± 125t§
LPS + eye 100 ng 1,240 ± 120 740 ± 171$
LPS + eye 10 ng 1,210 ± 130 733 ± 184*
LPS + dex 100 ng 540 ± 78§ 216 ± 50*§
LPS + dex 10 ng 715 ± 100§ 370 ± 90§
Control 6 ± 3 20 ± 6
NOTE. Production of TNF-a expressed in picograms per
milliliter. Values expressed as mean ± SEM.
Abbreviations: tac, tacrolimus; eye, cyclosporine; dex, dexa-
methasone.
*P < .05 in comparisons between patients and controls,
tP < .05 in comparisons between LPS stimulation and pre¬
incubation with different immunosuppressants.
$P < .01 in comparisons between patients and controls.
§P < .01 in comparisons between LPS stimulation and pre¬
incubation with different immunosuppressants.
table using a cutoff value of TNF-a! production of
1,260 pg/mL is listed in Table 3. Sensitivity was 78%,
specificity was 75%, positive predictive value was 0.70,
and negative predictive value was 0.81.
The effects of preincubation with the different
immunosuppressants in the inhibition or augmenta¬
tion ofTNF-a production are also listed in Table 1.
TNF-a production by patients was significantly in¬
hibited by dexamethasone, but not cyclosporine or
tacrolimus (all P = .000 with respect to either dose of
dexamethasone compared with LPS, both doses of
tacrolimus, and both doses of cyclosporine). Dexa-
LPS only cydO cyclOO dexlO dexlOO taclO tac100
Figure 1. Production of TNF-a pretransplantation by
patients with (n = 9) and without acute cellular rejection
(n = 12). Values shown as mean + SEM. *P < .05. **P <
0.01. (tac, tacrolimus; eye, cyclosporine; dex, dexametha¬
sone.)
methasone, 100 ng, significantly inhibited TNF-a
production more than did 10 ng of dexamethasone
(P = .000). In healthy controls, TNF-a production
was also significantly inhibited by dexamethasone in
a similar dose-dependent manner. However TNF-a
production was also inhibited by tacrolimus, 10 ng
(P = .008) and 100 ng (P = .04), but not cyclospor¬
ine, 10 ng (P = .18) or 100 ng {P = 1.00). The
differential effect of immunosuppressants led to sig¬
nificant differences in TNF-a production between
patients and controls that were not seen with LPS
alone.
There was no statistically significant difference in
the production ofTNF-a after LPS stimuladon in pa¬
tients with different causes of liver disease. Mean values
were 1,089 ± 200 pg/mL in patients with primary
biliary cirrhosis (n = 9), 1,315 ± 300 pg/mL in pa¬
tients with alcoholic liver disease (n = 6), 1,530 ± 140
pg/mL in patients with chronic viral disease (n = 4),
and 890 ± 270 pg/mL in patients with cryptogenic
cirrhosis (n = 2). No statistically significant difference
was observed between causes of liver disease in the ef¬
fects of preincubation with different immunosuppres¬
sants.
There was no correlation ofTNF-a productionwith
age or serum creatinine level.
In the 8 patients with less severe liver disease
(1 patient, Child's class A; 7 patients, Child's class B),
mean production ofTNF-a was 1,300 ± 225 pg/mL,
which was not significantly different from that of the 13
patients with Child's class C cirrhosis (1,170 ± 165
pg/mL; P = .6, Mann-Whitney Utest). No statistically
significant difference was seen in the effects of preincu¬
bation with different immunosuppressants in the dif¬
ferent Child's class groups.
IL-10
Production of IL-10 in patients (770 ± 160 pg/mL;
n — 18) and controls (522 ±130 pg/mL; n = 6) after
LPS stimulation was similar. Figure 2 shows there was
no difference in the amount of IL-10 produced pre¬
transplantation in patients who developed acute rejec-
Table 3. Contingency Table ofTNF-a Production
Pretransplantation and Acute Rejection
TNF-a (pg/mL) No Rejection Acute Rejection
<1,260 9 2
>1,260 3 7
NOTE. P = .03, Fisher's exact test.
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Figure 2. IL-10 production by patients with acute rejec¬
tion (n = 9) and no rejection (n = 9). Values shown as
mean + SEM. (tac, tacrolimus; eye, cyclosporine; dex,
dexamethasone.)
tion (715 ± 200 pg/mL) after transplantation and
those who did not develop rejection (835 — 260
pg/mL).
The effect ofpreincubation with different immuno¬
suppressants is listed in Table 4. IL-10 production in
patients was significantly inhibited by preincuba¬
tion with dexamethasone, 100 ng (P = .00) and 10 ng
(P — .00). Dexamethasone, 100 ng, significandy inhib¬
ited IL-10 production more than did 10 ng of dexa¬
methasone (.P = .02). IL-10 production was aug¬
mented by preincubation with tacrolimus, 10 ng (P =
.04) and 100 ng (P = .03). Cyclosporine had no signif¬
icant effect on production compared with LPS. In
healthy controls, dexamethasone inhibited IL-10 pro¬
duction, but there was no significant difference between
the 2 doses (P= .01 for both doses). Neither tacrolimus
nor cyclosporine had a significant effect on IL-10 pro¬
duction. There was a significant difference between lev¬
els of IL-10 in patients and controls only in the presence
of dexamethasone.
IL-10 production by PBMCs after LPS stimulation
was similar for patients with different causes of liver
disease. Mean values were 980 ± 380 pg/mL in patients
with primary biliary cirrhosis (n = 6), 910 ± 340
pg/mL in patients with alcoholic liver disease (n = 6),
520 ± 90 pg/mL in patients with chronic viral disease
(n = 4), and 570 ± 100 pg/mL in patients with cryp¬
togenic cirrhosis (n = 2). No statistically significant
difference was observed between causes of liver disease
in the effects of preincubation with different immuno-
suppresants.
In the 8 patients with less severe liver disease
(1 patient, Child's class A; 7 patients, Child's class B),
mean production of IL-10 was 1,080 ± 290 pg/mL,
which was not significantly different from the 10 pa¬
tients with Child's class C cirrhosis (530 ± 150 pg/mL;
P=.\).
Discussion
This study shows that pretransplantation TNF-a pro¬
duction from PBMCs stimulated by LPS is greater in
patients who go on to develop acute cellular rejection.
We also report a difference in response to tacrolimus in
patients and controls, with inhibition of TNF-a in
healthy controls but not patients, and augmentation of
IL-10 in patients but not controls. Dexamethasone in¬
hibited production of both cytokines by patients and
controls.
Cytokine levels in hepatic allografts with acute rejec¬
tion show differences from those grafts without rejec¬
tion. TNF-a, IL-5, and IL-67'8'1" levels have been
shown to be increased. The principal source ofTNF-a
is the monocyte/macrophage, although many other
cells produce this cytokine. In a study investigating
human liver allograft rejection, elevated plasmaTNF-a
levels occurred concomitantly with large numbers of
TNF-a-producing monocytes within the graft.16 Evi¬
dence also suggests that the principal source ofTNF-a
in acute rejection is recipient monocyte/macrophage
cells.17 The effect of TNF-a in the initiation of the
rejection process, presumably by activation ofendothe¬
lial cells and up-regulation of the expression ofadhesion
factors, is further suggested by the improved survival
seen in models in which monoclonal antibody against
TNF-a is administered posttransplantation.18 The
finding that TNF-a production pretransplantation is
increased in patients who then develop acute rejection is
Table 4. Production of IL-10 in Patients With Liver
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LPS + tac 10 ng
LPS + eye 100 ng
LPS + eye 10 ng
LPS + dex 100 ng















64 ± 21 ft
90 ± 35tt
20 ± 6
NOTE. IL-10 expressed in picograms per milliliter. Values
expressed as mean ± SEM.
Abbreviations: tac, tacrolimus; eye, cyclosporine; dex, dexa¬
methasone.
*P < .05 for comparisons between LPS stimulation and pre¬
incubation with immunosuppressants.
fP < .01 for comparisons between LPS stimulation and
preincubation with immunosuppressants.
%P < .05 for comparisons between patients and controls.
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interesting. The donor liver results in an alloimmune
response, the magnitude ofwhich results in either sig¬
nificant or insignificant acute rejection. As previously
indicated, TNF-a has a major role in this immune/
inflammatory reaction, and our results suggest that the
pretransplantation production capabilities of the trans¬
plant recipients may reflect the propensity for inflam¬
mation within the graft. However, IL-10 has more ofan
immunomodulatory function, and studies of liver
transplantation have indicated a reduction or no change
in the intragraft levels at times ofacute rejection. u>12 In
other solid-organ transplants, IL-10 may exacerbate re¬
jection,19 and anti-IL-10 monoclonal antibodies have
been shown to improve survival of heart transplants in
animal models.20
The influence of pretransplantation cytokine levels
on rejection has been investigated in renal transplanta¬
tion, with increased mean levels of interferon-y
(IFN-y) in the group going on to develop acute rejec¬
tion.21 However, TNF-a was not measured in this
study. Our study suggested that TNF-a production less
than 1,260 pg/mL predicted patients less likely to ex¬
perience acute rejection. The benefit of being able to
predict patients less likely to experience acute rejection
is that from day 1, immunosuppression could be re¬
duced, hopefully reducing such adverse effects as renal
impairment or infection. Evidence suggests that a single
episode of acute rejection improves graft survival.6 It is
therefore unlikely that reducing immunosuppression in
patients less likely to develop acute rejection will ad¬
versely affect their graft if they go on to have acute
rejection as a result.
The effect ofother pretransplantation parameters on
acute rejection was reported recently.6 In a large study,
pretransplantation creatinine level and recipient age
were found to be predictors of rejection, whereas other
studies have shown cause of liver disease to influence
rejection.22'23 Recipient age in this small study did not
quite reach statistical significance. There are no reports
ofTNF-a levels declining with age, and we found no
correlation of production with age or severity of liver
disease.
Long-term hepatic allograft survival has been greatly
enhanced by effective immunosuppressants, such as cy¬
closporin and tacrolimus. These compounds are struc¬
turally different and bind to separate intracellular recep¬
tors: cyclosporine to cyclophilin and tacrolimus to
FK506-binding protein 12. Their major immunosup¬
pressive effects appear to be through the inhibition of
calcineurin, a phosphatase, by the respective drug-im-
munophilin complex. There appears to be some differ¬
ence in the effects of these drugs in vitro, depending on
the cell type used and the inductor. In the case of
cytokine production, there are reports ofenhanced pro¬
duction of IL-6,3 whereas many other cytokines are
inhibited, e.g., IL-1/3, IL-2, IL-4, and IL-8.2
TNF-a production is inhibited in vitro by both
cyclosporine and tacrolimus in cells from healthy indi¬
viduals, although the mode of activation has been
shown to influence inhibition. Monocytes in one study
were not inhibited by cyclosporine or tacrolimus when
activated by LPS,24 although this has not been a univer¬
sal finding.3 The inhibition of TNF-a production by
tacrolimus and cyclosporine is partly through the inhi¬
bition ofcalcineurin.23 Our results suggest that patients
with liver disease do not reduce production ofTNF-a
from PBMCs after preincubation with calcineurin in¬
hibitors, whereas control patients do. It has been shown
that PBMCs from patientswith cirrhosis after resting in
vitro for 24 hours produce TNF-a levels similar to
those of healthy controls.26 It may be that this primed
state in patients with cirrhosis may overcome the pro¬
posed mechanism of inhibition by calcineurin inhibi¬
tors. The inhibition of TNF-a production by dexa-
methasone is likely to be a different mechanism
unaffected by liver disease. Other studies have shown
corticosteroids to be inhibitors ofother cytokines, with
no effect from either cyclosporine or tacrolimus.27
The differential effect of tacrolimus on the produc¬
tion of IL-10 in patients compared with healthy con¬
trols and with the other immunosuppressants is inter¬
esting. Studies of the effect of cyclosporine on IL-10
production are conflicting. In most studies,28'29 as in
ours, production is unchanged, although one study sug¬
gested an up-regulation.30 The literature on tacrolimus
is similarly conflicting, with reports of no effect31 and
an increase in production.32 The mechanisms that con¬
trol and regulate IL-10 production are still unclear.
Some studies report the up-regulation of IL-10 produc¬
tion by substance P,33 IFN-a,34 and IFN-/3.33 It is of
interest that the mouse II -10 gene has shown regula¬
tory motifs in the enhancer region similar to that in the
IL-6 enhancer region because tacrolimus has been
shown to enhance IL-6 production in human mono¬
cytes. IL-10 has been shown to suppress inflammatory
cytokine production in humans.36 It also down-regu¬
latesMHC class II molecule production in monocytes,
therefore inhibiting proliferative T-cell and cytotoxic
T-cell responses.37 It is possible that the effect of tacroli¬
mus on IL-10 production may contribute to the differ¬
ence in immunosuppressive capabilities between tac¬
rolimus and cyclosporine.
In conclusion, we report increased pretransplanta¬
tion levels of the proinflammatory cytokine, TNF-a, in
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the group of patients who develop acute cellular rejec¬
tion posttransplantation, suggesting that a patient's in¬
flammatory potential may have some influence on re¬
sponse to the allograft. Furthermore, we report
enhanced production of IL-10 by patients with liver
disease in the presence of tacrolimus and a lack of inhi¬
bition ofTNF-a production by cyclosporine and tac¬
rolimus. This indicates that studies investigating mech¬
anisms in healthy volunteers may not apply to patients.
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duration of vancomycin administration (18.4±7.9 vs. 17.3±8
days, P=0.566) and can only be explained by the timing of the
first doses of vancomycin, almost a week earlier in the pro¬
phylaxis group. We speculate that renal function may be
particularly vulnerable during the first days after the end of
the conditioning regimen so that the nephrotoxicity of van¬
comycin may be increased.
We conclude that GPB significantly contributes to overall
morbidity during the early post-BMT episode but has no
major impact on early mortality. The prophylactic use of
vancomycin reduces the risk of GPB, especially of potentially
fatal streptococcus sepsis. However, this advantage may be
outweighed by a negative impact on renal function, which
seems to be particularly vulnerable to vancomycin toxicity
within the first week after BMT. The results of our study
support a restrictive use ofvancomycin in the management of
neutropenia after BMT.
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THE EFFECT OF POLYMORPHISMS IN TUMOR NECROSIS
FACTOR-a, INTERLEUKIN-10, AND TRANSFORMING GROWTH
IFACTOR-/31 GENES IN ACUTE HEPATIC ALLOGRAFT REJECTION
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Background. The occurrence of acute rejection in
>rthotopic liver transplantation is unpredictable. The
•ole of cytokines in the process of rejection is not
;ntirely clear. We investigated polymorphisms in the
genes encoding tumor necrosis factor (TNF)-«, inter-
eukin (IL)-IO, and transforming growth factor (TGF)-
=41, which affect the amount of cytokine produced in
ritro, in a liver transplant population to determine
iny association with acute rejection.
Method. DNA was extracted from whole blood of
iver transplant patients. After amplification with
)olymerase chain reactions, the polymorphisms at
NF-o -308, IL-10 -1082, and TGF-/31 +869 and +915
vere determined using sequence-specific oligonucleo-
ide probes. Acute cellular rejection was a clinical and
'
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histological diagnosis.
Results. Acute cellular rejection requiring treatment
occurred in 68 (48%) of 144 patients. Acute cellular
rejection was significantly associated with the TNF-n
-308 A/A genotype (P<0.02). There was no signifies.;)!
association with either IL-10 or TGF-/31 polyu:
phisms in acute rejection.
Conclusion. Patients with a homozygous TNF-a -308
genotype A/A are more likely to suffer from acute cel¬
lular rejection after liver transplantation.
Acute cellular rejection after orthotopic liver transplanta¬
tion occurs in about 50% of recipients (1). Cytokines play a
major role in the inflammation and immune responses that
take place in allorecognition and rejection. There are a num¬
ber of cytokines that have been implicated in these re¬
sponses. The proinflammatory cytokines tumor necrosis fac¬
tor (TNF)-o and interleukin (IL)-6 can cause endothelial cell
activation, up-regulate cell adhesion molecules and MHC
expression, as well as recruit other immune cells to the site of
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flammation. Other cytokines, such as IL-4 and IL-10, may
ive a modulatory function.
IL-10 inhibits the proliferation ofT cells by inhibiting IL-2
oduction and reducing the synthesis of proinflammatory
tokines such as TNF-a, IL-6, and IL-1/3. It also down-
gulates surface expression of MHC class II molecules on
itigen-presenting cells.
There is evidence for increased production of TNF-a in
itients undergoing acute cellular rejection after orthotopic
rer transplantation in both measurement of serum levels
id intragraft messenger RNA (2, 3). Other studies have
vealed increased intragraft expression of other proinflam-
atory cytokines such as IL-6 (4). The measurement of IL-10
serum and graft have shown no changes during liver
lograft rejection (5, 6), although one study suggested an
crease before episodes of acute rejection (7).
An individual's propensity to develop acute rejection after
rer transplantation is difficult to predict. One possible rea-
n for individual variation may be differences in cytokine
•oduction related to polymorphisms in cytokine genes. We
vestigated polymorphisms known to affect the production
cytokines in vitro for the cytokines TNF-a (8), IL-10 (9),
id transforming growth factor (TGF)-)31 (10) in a liver
ansplant population with respect to acute rejection.
Patients underwent transplantation at the Scottish Liver
-ansplant Unit between November 1992 and November
(98. All patients were adults receiving primary transplants,
lere were no ABO-incompatible transplants in this group,
imunosuppression was with triple-drug therapy consisting
cyclosporine or tacrolimus, azathioprine (1-2 mg/kg), and
ednisolone (20 mg tapering to 5 mg at 3 months after
ansplantation).
Acute rejection was defined as rejection treated with high-
>se corticosteroids based upon clinical, biochemical, and
stological evidence—using the accepted Banff criteria,
ironic rejection was diagnosed histologically—foamy cell
•tenopathy and/or 50% of portal tracts without a bile duct,
le technical aspects of determining cytokine genotypes are
hailed elsewhere (11).
Briefly, genomic DNA was obtained from EDTA anticoag-
ated whole blood by phenol extraction and ethanol precip¬
itin after proteinase K (Boehringer Mannheim, Mann-
:im, Germany) digestion. DNA was amplified by a
ilymerase chain reaction carried out using standard tech-
ques.
After specific polymerase chain reaction reactions were
■rformed, two 5' biotinylated oligonucleotide probes (Geno-
s Biotechnologies Ltd, Pampisford, UK) were used to pos-
ively identify each polymorphism in cytokine gene promot¬
es by sequence-specific oligonucleotide probing. The
ilvmorphisms we investigated in the TNF-a and IL-10
■nes were those located in the promoter regions at position
308 (G to A) and -1082 (G to A), respectively, relative to
e transcription start site. The homozygous genotype TNF-a
508 A/A is associated with high production of TNF-a, and
e homozygous genotype IL-10 - 1082 G/G is associated
iih high production of IL-10. The polymorphisms for
5 F-j3, were those located in the leader sequence at position
869 (C to T) and position +915 (G to C). The polymorphisms
■ 869 result in leucine (T) or proline (C) residues at codon
i in the protein signal sequence, with the former associated
nh high production of TGF-/31. Polymorphisms at position
+915 result in either an arginine (G) or leucine (C), with
arginine at codon 25 associated with high production. Het-
erozygotes produce intermediate amounts of the respective
cytokines.
Statistical analysis was carried out using chi-square tests,
with a value ofP<0.05 deemed as significant. The Bonferroni
correction was applied in multiple comparisons. Analysis of
genotypes was carried out in 144 patients who received a
transplant.
The overall incidence of acute cellular rejection in this
group was 48%. The incidence of acute rejection in the dif¬
ferent etiologies is shown in Table 1. No significant associa¬
tion between acute rejection and HLA DR mismatches was
found.
The occurrence of acute rejection in patients with the dif¬
ferent TNF-a genotypes is shown in Table 2. The results for
the IL-10 and TGF-j31 genotypes are shown in Tables 3 and
4. There was a significant difference between the rejection
and nonrejection groups with respect to the TNF-a -308
genotype. The increased incidence of acute rejection was in
those patients who were homozygous A/A (P<0.02, Bonfer¬
roni correction). When acute rejection was further classified
as a single episode or recurrent, there was no significant
difference between genotypes, with recurrent acute rejection
occurring in six, eight, and two patients for the genotypes
G/G, G/A, and A/A, respectively. Combining the TNF-a geno¬
type with the IL-10 genotype did not show significant differ¬
ences between groups (data not shown).
Chronic rejection occurred in only six patients. This group
was not thought large enough to subject to any meaningful
analysis.
Acute rejection after liver transplantation is an unpredict¬
able event that often requires treatment with an increase in
immunosuppression usually in the form of high-dose cortico¬
steroids. The ability to predict which patients are more likely
to suffer from acute rejection may allow individualization of
immunosuppression, therefore preventing over immunosup¬
pression in patients less likely to develop rejection. A single
episode of acute rejection does not seem to adversely affect
long-term graft outcome (12, 13).
The role of polymorphisms in individual cytokine genes
that influence production of that cytokine is largely unknown
with respect to acute cellular rejection in liver transplanta¬
tion. This may have some bearing on future immunosuppres¬
sive strategies if there is a relation between genotype and
rejection.
The proinflammatory cytokine TNF-a has many effects in
the inflammatory process, and there is evidence to suggest
that the polymorphism at position -308 in the promoter
Table 1. The occurrence of acute rejection according to
etiology of liver disease
etiology
Primary biliary cirrhosis (n 61)
Alcoholic liver disease (n 25)
Primary sclerosing cholangitis (n 16)
Autoimmune hepatitis (n - 8)
Chronic viral hepatitis (n = 7)
Acute liver failure (n 20)
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Table 2. The incidence of acute rejection with respect to
the TNF-a - 308 genotype
TNF-a - 308 genotype G/G A/G A/A
No acute rejection 42 30 4
Acute rejection 28 25 15"
" P < 0.02 (Bonferroni correction).
Table 3. Acute rejection with respect to the IL-10 - 1082
genotype (not significant)
IL-10 - 1082 genotype A/A A/G G/G
No acute rejection 22 38 16
Acute rejection 16 30 22
Table 4. Acute rejection with respect to the TGF-jJl +869
and +915 genotype (not significant)
TGF-/31 +869 TGF-/31 +915
genotype genotype
C/C C/T T/T C/C C/G G/G
No rejection 8 36 32 1 11 64
Acute rejection 10 35 23 3 9 56
region of the gene influences disease. Individuals possessing
the so-called TNF2 genotype (—308 A) have been shown to
have worse outcome in cerebral malaria and non-Hodgkin's
lymphoma (14, 15). The influence of this polymorphism in
rejection of solid organ allografts has been reported in both
kidney and heart transplantation (16, 17), the latter only
showing a statistical difference when combined with the
IL-10 genotype. This is the first report of an effect in liver
transplantation, although a recent study reported no effect of
another polymorphism, the so-called Ncol polymorphism in
the TNF-/3 gene, on the occurrence ofacute rejection (18). The
large increase in relative risk associated with cerebral ma¬
laria (14) outcome was associated with the homozygous
TNF2 genotype, and it may be that this genotype has more of
an effect on TNF-a production than the Ncol polymorphism.
The finding that 79% of patients who were homozygous for
TNF2 required treatment for acute rejection compared with
40% of patients who were homozygous for TNF1 suggests
that the TNF2 genotype may predispose to the occurrence of
acute cellular rejection in liver transplantation. The finding
that there was no difference in genotypes in patients with
recurrent acute rejection may indicate that the initial recip¬
ient recognition of donor antigen is the only response influ¬
enced to a sufficient level by the TNF-a genotype.
The role of IL-10 in acute cellular rejection is not straight¬
forward. It has many anti-inflammatory properties, and one
may therefore expect that a polymorphism leading to high
production both in vitro (10) and in vivo (19) may protect
against acute rejection. However the studies investigating
IL-10 in acute rejection in liver transplantation both in the
graft and serum have failed to show differences between
grafts with or without rejection. Studies investigating acute
renal allograft rejection have shown increased IL-10 intra¬
graft expression (20, 21), and the recent study reporting
cytokine genotypes in renal allografts showed an increase in
rejection in the polymorphism associated with high IL-10
production (16). Cardiac allografts in animal studies have
shown an exacerbation of rejection with the addition of IL-10,
and the measurement of intragraft levels of IL-10 in h an
grafts does not predict acute rejection (22). As already indi¬
cated, the single study of cytokine genotyping in heart trans¬
plantation has shown that a combination of a genotype cor¬
responding to high TNF-a production and low IL-10
production was associated with high levels of rejection in the
early posttransplantation period (17). There was, however,
no reduced rejection in those with the high IL-10 producer
genotype. The effect that IL-10 has on B cells, causing them
to proliferate and increase the humoral response, may be
important in renal transplantation; this may be one of the
reasons for the apparent difference in the effect of IL-10 in
the rejection of different organs.
In our study there is no evidence that IL-10 polymorphisms
either alone or in combination with specific TNF-a polymor¬
phisms influence the occurrence of acute cellular rejection.
There is a widespread belief that acute cellular rejection n
hepatic allografts is different from that in other solid organ
allografts as evidenced by the lack of requirement for HLA
matching and the improved outcome of grafts suffering a single
episode of acute rejection (12, 13). Therefore it may not be too
surprising that the influence of polymorphisms differs between
organs.
TGF-/3 is a cytokine with immunosuppressive and profibrotic
actions. The data presented suggest no influence of the TGF-/B1
genotype on acute rejection. There is evidence to suggest that in
the case of lung allografts, there is a significant effect on graft
outcome with respect to lung fibrosis, which is influenced by the
TGF-/3 genotype (10), and recent evidence also suggests an
effect on cardiac transplant vasculopathy (23). Chronic rejection
ofhepatic allografts is not common and it occurred in less than
5% of this study population. Chronic rejection of hepatic allo¬
grafts is not common and it occurred in less than 5% of his
study population. Larger numbers of patients will be requ red
to determine whether the TGF-/3I genotype influences hepatic
allografts in a similar fashion.
In conclusion we report the first study of cytokine geno¬
types in a liver transplant population, showing that TNF-a
polymorphism associated with high production is signifi¬
cantly associated with acute cellular rejection. The influence
of these findings on clinical practice is not clear at present
but may help with tailoring immunosuppressive strategies.
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TRANSFORMING GROWTH FACTOR /3 AND INTERLEUKIN-10
SUBVERT ALLOREACTIVE DELAYED TYPE HYPERSENSITIVITY
IN CARDIAC ALLOGRAFT ACCEPTOR MICE1
Alice A. Bickerstaff,2,6 Anne M. VanBuskirk,2,5 Elaine Wakely,2 and Charles G. Orosz2~5
The Ohio State University College ofMedicine, Departments of Surgery, Pathology, and
Medical Microbiology and Immunology, and the Comprehensive Cancer Center, Columbus, Ohio 43210
We have previously reported that temporary treat¬
ment of cardiac allograft recipients with gallium ni¬
trate (GN) results in indefinite graft survival, and the
inability to mount donor-reactive delayed type hyper¬
sensitivity (DTH) responses. We report that antibodies
to either transforming growth factor-/! (TGF/i) or in¬
terleukin-10 (IL10) can uncover DTH responses to do¬
nor alloantigens in cardiac allograft acceptor mice.
The DTH responses uncovered with TGF/!-reactive an¬
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tibodies can be blocked by exogenous IL10, and those
uncovered with ILlO-reactive antibodies can be
blocked by exogenous TGF/!. These data demonstrate
that allograft acceptor mice are fully allosensitized,
and poised to make donor-reactive cell-mediated im¬
mune responses. However, such responses are sub¬
verted by a donor alloantigen-dependent mechanism
that involves TGF/5 and IL10, which in turn interfere
with local cell-mediated immune responses.
The acute rejection of murine cardiac allografts can be
blocked by short-term treatment of the allograft recipients
with selected immunosuppressive agents, including anti-
CD4 monoclonal antibody (7, 2) and gallium nitrate (GN) (3,
4). Despite numerous studies on this phenomenon, little is
known about the immunological mechanisms that operate to
prevent acute allograft rejection under these conditions. We
and others have demonstrated that the mechanism of allo¬
graft acceptance is: (1) mediated by an active, antigen-depen¬
dent immunologic process that overtly protects the allograft,
(2) transferable via splenocytes to severe combined immuno-
